GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: June 1, 2004, 08:19:45 ; Search time 55 Seconds
(without alignments)
462.350 Million cell updates/sec

Title: US-09-989-293A-377
Perfect score: 462
Sequence: 1 MTFFLSLLLLLVCEAIWRSN.....DSRGLILGAEAWGRGVKKNT 90

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1586107 seqs, 282547505 residues

Total number of hits satisfying chosen parameters: 1586107

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 206 summaries

Database : A_Geneseq_29Jan04:*
1: geneseqp1980s:*
2: geneseqp1990s:*
3: geneseqp2000s:*
4: geneseqp2001s:*
5: geneseqp2002s:*
6: geneseqp2003as:*
7: geneseqp2003bs:*
8: geneseqp2004s:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	462	100.0	90	3	AAY66748	Aay66748 Membrane-
2	462	100.0	90	3	AAB33469	Aab33469 Human PRO
3	462	100.0	90	4	AAU12408	Aau12408 Human PRO
4	462	100.0	90	4	AAB50922	Aab50922 Human PRO
5	462	100.0	90	4	AAB65271	Aab65271 Human PRO
6	462	100.0	90	6	ABU58086	Abu58086 Human PRO
7	462	100.0	90	6	ABU59164	Abu59164 Novel hum
8	462	100.0	90	6	ABU82676	Abu82676 Human sec
9	462	100.0	90	6	ABO17852	Abo17852 Novel hum
10	462	100.0	90	6	ABU60595	Abu60595 Human sec
11	462	100.0	90	6	ABU13977	Abu13977 Human PRO
12	462	100.0	90	6	ABU81106	Abu81106 Human PRO
13	462	100.0	90	6	ABU72562	Abu72562 Novel hum
14	462	100.0	90	6	ABU66806	Abu66806 Human PRO
15	462	100.0	90	6	ABU59887	Abu59887 Novel sec
16	462	100.0	90	6	ABU59311	Abu59311 Human sec
17	462	100.0	90	6	ABO26008	Abo26008 Human PRO
18	462	100.0	90	6	ABO25077	Abo25077 Human sec
19	462	100.0	90	6	ABU59017	Abu59017 Human sec
20	462	100.0	90	6	ABU92395	Abu92395 Novel hum
21	462	100.0	90	6	ABU59460	Abu59460 Novel hum
22	462	100.0	90	6	ABU67082	Abu67082 Human sec
23	462	100.0	90	6	ABU92226	Abu92226 Novel hum
24	462	100.0	90	6	ABU10932	Abu10932 Human PRO
25	462	100.0	90	6	ABU81684	Abu81684 Novel hum
26	462	100.0	90	6	ABU88623	Abu88623 Human sec
27	462	100.0	90	6	ABO34137	Abo34137 Human PRO
28	462	100.0	90	6	ADA45993	Ada45993 Novel hum
29	462	100.0	90	6	ADA76424	Ada76424 Human PRO
30	462	100.0	90	6	ADA19074	Ada19074 Human PRO
31	462	100.0	90	6	ADA61697	Ada61697 Homo sapi
32	462	100.0	90	6	ADB19482	Adb19482 Novel hum
33	462	100.0	90	6	ADB28023	Adb28023 Human PRO
34	462	100.0	90	6	ADA86502	Ada86502 Novel hum
35	462	100.0	90	6	ADB16066	Adb16066 Human PRO
36	462	100.0	90	6	ADA37888	Ada37888 Human sec
37	462	100.0	90	6	ADA47852	Ada47852 Human PRO
38	462	100.0	90	6	ADA21574	Ada21574 Human sec
39	462	100.0	90	6	ADA10361	Ada10361 Human sec
40	462	100.0	90	6	ADA67647	Ada67647 Human PRO
41	462	100.0	90	6	ADB30654	Adb30654 Human PRO
42	462	100.0	90	6	ADA85950	Ada85950 Novel hum
43	462	100.0	90	6	ADA17905	Ada17905 Human PRO
44	462	100.0	90	6	ADA97162	Ada97162 Human PRO
45	462	100.0	90	6	ADA79466	Ada79466 Human PRO
46	462	100.0	90	6	ADA87605	Ada87605 Novel hum
47	462	100.0	90	6	ADB16807	Adb16807 Human PRO
48	462	100.0	90	6	ADA28013	Ada28013 Human sec
49	462	100.0	90	6	ADA91899	Ada91899 Novel hum
50	462	100.0	90	6	ADB14962	Adb14962 Human PRO
51	462	100.0	90	6	ADB18923	Adb18923 Novel hum
52	462	100.0	90	6	ADA94138	Ada94138 Human PRO
53	462	100.0	90	6	ADB20034	Adb20034 Novel hum
54	462	100.0	90	6	ADB13346	Adb13346 Human PRO
55	462	100.0	90	6	ABO43385	Abo43385 Novel hum
56	462	100.0	90	6	ADA94593	Ada94593 Human sec
57	462	100.0	90	6	ADA74600	Ada74600 Human PRO
58	462	100.0	90	6	ADB24833	Adb24833 Human PRO
59	462	100.0	90	6	ADA82357	Ada82357 Human PRO
60	462	100.0	90	6	ADA75320	Ada75320 Human PRO
61	462	100.0	90	6	ADA85398	Ada85398 Novel hum
62	462	100.0	90	6	ADA84846	Ada84846 Novel hum
63	462	100.0	90	6	ADB30102	Adb30102 Human PRO
64	462	100.0	90	6	ADA80630	Ada80630 Human PRO
65	462	100.0	90	6	ADA75872	Ada75872 Human PRO
66	462	100.0	90	6	ADA38818	Ada38818 Human sec
67	462	100.0	90	6	ADA47097	Ada47097 Human PRO
68	462	100.0	90	6	ADB25393	Adb25393 Human PRO
69	462	100.0	90	6	ADA93569	Ada93569 Human PRO
70	462	100.0	90	6	ADB26919	Adb26919 Human PRO
71	462	100.0	90	6	ADB31206	Adb31206 Human PRO
72	462	100.0	90	6	ADA92939	Ada92939 Human sec
73	462	100.0	90	6	ADA61134	Ada61134 Homo sapi
74	462	100.0	90	6	ADB24281	Adb24281 Human PRO
75	462	100.0	90	6	ADA96610	Ada96610 Human PRO
76	462	100.0	90	6	ADA81182	Ada81182 Human PRO
77	462	100.0	90	6	ADA96058	Ada96058 Human PRO
78	462	100.0	90	6	ADB26367	Adb26367 Human PRO
79	462	100.0	90	6	ADB21852	Adb21852 Novel hum
80	462	100.0	90	7	ADA77631	Ada77631 Human PRO
81	462	100.0	90	7	ADB18371	Adb18371 Human PRO
82	462	100.0	90	7	ADA87054	Ada87054 Novel hum
83	462	100.0	90	7	ADA88157	Ada88157 Novel hum
84	462	100.0	90	7	ADA46545	Ada46545 Novel hum
85	462	100.0	90	7	ADB28575	Adb28575 Human PRO
86	462	100.0	90	7	ADB29127	Adb29127 Human PRO
87	462	100.0	90	7	ABO53223	Abo53223 Human sec
88	462	100.0	90	7	ADA77079	Ada77079 Human PRO
89	462	100.0	90	7	ADA22500	Ada22500 Human sec
90	462	100.0	90	7	ADA88709	Ada88709 Novel hum
91	462	100.0	90	7	ADA97714	Ada97714 Human PRO
92	462	100.0	90	7	ADB27471	Adb27471 Human PRO
93	462	100.0	90	7	ADB22404	Adb22404 Novel hum
94	462	100.0	90	7	ABO22593	Abo22593 Human sec
95	462	100.0	90	7	ADA06666	Ada06666 Human sec
96	462	100.0	90	7	ADA39359	Ada39359 Human sec
97	462	100.0	90	7	ADA67095	Ada67095 Human PRO
98	462	100.0	90	7	ADB22956	Adb22956 Human PRO

99	462	100.0	90	7	ADB23729	Adb23729 Human PRO
100	462	100.0	90	7	ADA92451	Ada92451 Novel hum
101	462	100.0	90	7	ADB15514	Adb15514 Human PRO
102	462	100.0	90	7	ADB38766	Adb38766 Novel hum
103	462	100.0	90	7	ADB96385	Adb96385 Human PRO
104	462	100.0	90	7	ADB38214	Adb38214 Novel hum
105	462	100.0	90	7	ADB66686	Adb66686 Novel hum
106	462	100.0	90	7	ADB89766	Adb89766 Human PRO
107	462	100.0	90	7	ADB90498	Adb90498 Human PRO
108	462	100.0	90	7	ADB39599	Adb39599 Novel hum
109	462	100.0	90	7	ADB47222	Adb47222 Novel hum
110	462	100.0	90	7	ADB86829	Adb86829 Human PRO
111	462	100.0	90	7	ADB77434	Adb77434 Novel hum
112	462	100.0	90	7	ADB34591	Adb34591 Human PRO
113	462	100.0	90	7	ADB35695	Adb35695 Human PRO
114	462	100.0	90	7	ADB34039	Adb34039 Human PRO
115	462	100.0	90	7	ADB35143	Adb35143 Human PRO
116	462	100.0	90	7	ADB36247	Adb36247 Human PRO
117	462	100.0	90	7	ADB46642	Adb46642 Novel hum
118	462	100.0	90	7	ADC57857	Adc57857 Human PRO
119	462	100.0	90	7	ADC55221	Adc55221 Human PRO
120	462	100.0	90	7	ADC12088	Adc12088 Human sec
121	462	100.0	90	7	ADC56510	Adc56510 Human PRO
122	462	100.0	90	7	ADC07565	Adc07565 Human sec
123	462	100.0	90	7	ADC11555	Adc11555 Human sec
124	462	100.0	90	7	ADC50515	Adc50515 Novel hum
125	462	100.0	90	7	ADC72062	Adc72062 Novel hum
126	462	100.0	90	7	ADC60041	Adc60041 Novel hum
127	462	100.0	90	7	ADC53048	Adc53048 Novel hum
128	462	100.0	90	7	ADC57402	Adc57402 Novel hum
129	462	100.0	90	7	ADC60593	Adc60593 Novel hum
130	462	100.0	90	7	ADC51068	Adc51068 Novel hum
131	462	100.0	90	7	ADC65595	Adc65595 Human PRO
132	462	100.0	90	7	ADC54693	Adc54693 Novel hum
133	462	100.0	90	7	ADC53654	Adc53654 Novel hum
134	462	100.0	90	7	ADC59177	Adc59177 Novel hum
135	462	100.0	90	7	ADC56055	Adc56055 Novel hum
136	462	100.0	90	7	ADC58625	Adc58625 Novel hum
137	462	100.0	90	7	ADC14677	Adc14677 Novel hum
138	462	100.0	90	7	ADD08209	Add08209 Novel hum
139	462	100.0	90	7	ADD03299	Add03299 Novel hum
140	462	100.0	90	7	ADC90291	Adc90291 Novel hum
141	462	100.0	90	7	ADC82034	Adc82034 Human PRO
142	462	100.0	90	7	ADC69710	Adc69710 Human PRO
143	462	100.0	90	7	ADC48599	Adc48599 Human PRO
144	462	100.0	90	7	ADD10128	Add10128 Human PRO
145	462	100.0	90	7	ADD07676	Add07676 Novel hum
146	462	100.0	90	7	ADD04703	Add04703 Novel hum
147	462	100.0	90	7	ADC82567	Adc82567 Human PRO
148	462	100.0	90	7	ADC80659	Adc80659 Novel hum
149	462	100.0	90	7	ADD11166	Add11166 Human PRO
150	462	100.0	90	7	ADC48047	Adc48047 Human PRO
151	462	100.0	90	7	ADD08747	Add08747 Novel hum
152	462	100.0	90	7	ADC80107	Adc80107 Novel hum
153	462	100.0	90	7	ADD06996	Add06996 Novel hum
154	462	100.0	90	7	ADD09576	Add09576 Human PRO
155	462	100.0	90	7	ADC83243	Adc83243 Human PRO
156	462	100.0	90	7	ADD41289	Add41289 Novel hum
157	462	100.0	90	7	ADD52428	Add52428 Human PRO
158	462	100.0	90	7	ADD53168	Add53168 Human PRO
159	462	100.0	90	7	ADD53720	Add53720 Novel hum
160	462	100.0	90	7	ADD55350	Add55350 Human PRO
161	462	100.0	90	7	ADD56308	Add56308 Human PRO
162	462	100.0	90	7	ADD51876	Add51876 Human PRO
163	462	100.0	90	7	ADD02675	Add02675 Human PRO
164	462	100.0	90	7	ADD02109	Add02109 Human PRO
165	462	100.0	90	7	ADD54291	Add54291 Novel hum
166	462	100.0	90	7	ADD54746	Add54746 Human PRO
167	462	100.0	90	7	ADD92608	Add92608 Human PRO
168	462	100.0	90	7	ADD91504	Add91504 Human PRO
169	462	100.0	90	7	ADE04118	Ade04118 Human PRO
170	462	100.0	90	7	ADE26900	Ade26900 Novel hum
171	462	100.0	90	7	ADE32415	Ade32415 Novel hum
172	462	100.0	90	7	ADE22347	Ade22347 Human PRO
173	462	100.0	90	7	ADD79571	Add79571 Human PRO
174	462	100.0	90	7	ADE42107	Ade42107 Human PRO
175	462	100.0	90	7	ADE17924	Ade17924 Human PRO
176	462	100.0	90	7	ADD92056	Add92056 Human PRO
177	462	100.0	90	7	ADE33519	Ade33519 Novel hum
178	462	100.0	90	7	ADE34071	Ade34071 Novel hum
179	462	100.0	90	7	ADD80123	Add80123 Human PRO
180	462	100.0	90	7	ADD93160	Add93160 Human PRO
181	462	100.0	90	7	ADE19580	Ade19580 Human PRO
182	462	100.0	90	7	ADE19028	Ade19028 Human PRO
183	462	100.0	90	7	ADE43224	Ade43224 Human PRO
184	462	100.0	90	7	ADD96013	Add96013 Human PRO
185	462	100.0	90	7	ADE22899	Ade22899 Human PRO
186	462	100.0	90	7	ADD79017	Add79017 Human PRO
187	462	100.0	90	7	ADE26367	Ade26367 Novel hum
188	462	100.0	90	7	ADE32967	Ade32967 Novel hum
189	462	100.0	90	7	ADE42659	Ade42659 Human PRO
190	462	100.0	90	7	ADD80675	Add80675 Human PRO
191	462	100.0	90	7	ADD89703	Add89703 Human PRO
192	462	100.0	90	7	ADE40987	Ade40987 Human PRO
193	462	100.0	90	7	ADE04786	Ade04786 Human PRO
194	462	100.0	90	8	ADC81211	Adc81211 Novel hum
195	462	100.0	90	8	ADD76659	Add76659 Human PRO
196	462	100.0	90	8	ADD88023	Add88023 Human PRO
197	462	100.0	90	8	ADD86427	Add86427 Human PRO
198	462	100.0	90	8	ADE75875	Ade75875 Human PRO
199	462	100.0	90	8	ADE23451	Ade23451 Human PRO
200	462	100.0	90	8	ADE24003	Ade24003 Human PRO
201	462	100.0	90	8	ADE24646	Ade24646 Human PRO
202	462	100.0	90	8	ADD87471	Add87471 Human PRO
203	462	100.0	90	8	ADE89337	Ade89337 Human PRO
204	462	100.0	90	8	ADE18476	Ade18476 Human PRO
205	462	100.0	90	8	ADE88785	Ade88785 Human PRO
206	247.5	53.6	222	4	AAU19838	Aau19838 Human nov

ALIGNMENTS

RESULT 1
AAY66748
ID AAY66748 standard; protein; 90 AA.
XX
AC AAY66748;
XX
DT 05-APR-2000 (first entry)
XX
DE Membrane-bound protein PRO1159.
XX
KW Membrane-bound polypeptide; PRO polypeptide; LDL receptor; TIE ligand;
KW pharmaceutical; receptor immunoadhesin; gene mapping.
XX
OS Homo sapiens.
XX
PN WO9963088-A2.
XX
PD 09-DEC-1999.
XX
PF 02-JUN-1999; 99WO-US012252.
XX
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.

PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088722P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088740P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088811P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088825P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088863P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089090P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090461P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090538P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090688P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090691P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091358P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091486P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 12-JAN-1999; 99US-0115565P.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker K, Chen J, Goddard A, Gurney AL, Smith V, Watanabe CK;
PI Wood WI, Yuan J;
XX
DR WPI; 2000-072883/06.
DR N-PSDB; AAZ65094.
XX
PT Membrane-bound proteins and related nucleotide sequences.
XX
PS Claim 12; Fig 272; 822pp; English.
XX
CC The invention provides membrane-bound PRO polypeptides and
CC polynucleotides encoding them. The PRO sequences of the invention were
CC identified based on extracellular domain homology screening. The PRO
CC sequences have homology with proteins including LDL receptors, TIE
CC ligands and various enzymes. The membrane-bound proteins and receptor
CC molecules are useful as pharmaceutical and diagnostic agents. Receptor
CC immunoadhesins, for instance, can be used as therapeutic agents to block
CC receptor-ligand interactions. The membrane-bound proteins can also be
CC employed for screening of potential peptide or small molecule inhibitors

```
CC   of the relevant receptor/ligand interaction. The PRO encoding sequences
CC   are useful as hybridization probes, in chromosome and gene mapping and in
CC   the generation of antisense RNA and DNA. PRO nucleic acid sequences will
CC   also be useful for the preparation of PRO polypeptides, especially by
CC   recombinant techniques
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 3;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 2
AAB33469
ID   AAB33469 standard; protein; 90 AA.
XX
AC   AAB33469;
XX
DT   29-JAN-2001  (first entry)
XX
DE   Human PRO1159 protein UNQ589 SEQ ID NO:273.
XX
KW   Human; immune related disease; diagnosis; antiinflammatory; cardiant;
KW   dermatological; antiarthritic; antirheumatic; immunosuppressive;
KW   haemostatic; antithyroid; antidiabetic; nootropic; neuroprotective;
KW   antianaemic; hepatotropic; virucide; antipsoriatic; antiallergic;
KW   antiasthmatic; systemic lupus erythematosus; rheumatoid arthritis;
KW   osteoarthritis; spondyloarthropathy; systemic sclerosis; sarcoidosis;
KW   idiopathic inflammatory myopathy; Sjogren's syndrome; thyroiditis;
KW   systemic vasculitis; autoimmune haemolytic anaemia; diabetes mellitus;
KW   autoimmune thrombocytopaenia; immune-mediated renal disease;
KW   demyelinating disease; hepatobiliary disease; Whipple's disease;
KW   inflammatory bowel disease; gluten-sensitive enteropathy;
KW   autoimmune disease; immune-mediated skin disease; allergic disease;
KW   immunological disease; transplantation associated disease;
KW   graft rejection; graft-versus-host-disease.
XX
OS   Homo sapiens.
XX
PN   WO200053758-A2.
XX
PD   14-SEP-2000.
XX
PF   02-MAR-2000; 2000WO-US005841.
XX
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99US-0123618P.
PR   12-MAR-1999;   99US-0123957P.
PR   23-MAR-1999;   99US-0125775P.
PR   12-APR-1999;   99US-0128849P.
PR   20-APR-1999;   99WO-US008615.
PR   28-APR-1999;   99US-0131445P.
PR   04-MAY-1999;   99US-0132371P.
PR   14-MAY-1999;   99US-0134287P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-OCT-1999;   99US-0162506P.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030999.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Goddard A,  Gurney AL,  Hebert C,  Henzel W;
PI   Kabakoff RC,  Lu Y,  Pan J,  Pennica D,  Shelton DL,  Smith V;
PI   Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Yan M;
XX
DR   WPI; 2000-572271/53.
DR   N-PSDB; AAC58634.
XX
PT   Sixty four PRO polypeptides, useful in the diagnosis and treatment of
PT   immune related disorders, e.g. systemic lupus erythematosis, rheumatoid
PT   arthritis, osteoarthritis, thyroiditis and diabetes mellitus.
XX
PS   Claim 33; Fig 112; 309pp; English.
XX
CC   The present invention describes sixty four human PRO proteins which can
CC   be used in the treatment of immune related diseases. The human PRO
CC   proteins, anti-PRO antibodies, agonists and antagonists are useful for
CC   treating and diagnosing immune related disorders. The disorders are
CC   selected from systemic lupus erythematosus, rheumatoid arthritis,
CC   osteoarthritis, juvenile chronic arthritis, spondyloarthropathies,
CC   systemic sclerosis, idiopathic inflammatory myopathies, Sjogren's
CC   syndrome, systemic vasculitis, sarcoidosis, autoimmune haemolytic
CC   anaemia, autoimmune thrombocytopaenia, thyroiditis, diabetes mellitus,
CC   immune-mediated renal disease, demyelinating diseases of the central and
CC   peripheral nervous systems, hepatobiliary diseases, inflammatory bowel
CC   disease, gluten-sensitive enteropathy and Whipple's disease, autoimmune
CC   or immune-mediated skin diseases, allergic diseases, immunological
CC   diseases of the lung, and transplantation associated diseases including
CC   graft rejection and graft-versus-host-disease. AAC58397 to AAC58578
CC   represent PCR primers and hybridisation probes used in the isolation of
CC   human PRO sequences. AAC58579 to AAC58642 and AAB33414 to AAB33477
CC   represent human PRO polynucleotide and protein sequences given in the
CC   exemplification of the present invention
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 3;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 3
AAU12408
```

ID AAU12408 standard; protein; 90 AA.
XX
AC AAU12408;
XX
DT 24-OCT-2001 (first entry)
XX
DE Human PRO1159 polypeptide sequence.
XX
KW Human secretory and transmembrane; PRO; mammalian; cancer; lung; breast;
KW prostate; cervical; tumour necrosis factor-alpha; TNF-alpha; cartilage;
KW ear; proliferation; glucose; free fatty acid; skeletal muscle; adipocyte;
KW A-peptide; factor VIIA; gene therapy.
XX
OS Homo sapiens.
XX
PN WO200140466-A2.
XX
PD 07-JUN-2001.
XX
PF 01-DEC-2000; 2000WO-US032678.
XX
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 09-DEC-1999; 99US-0170262P.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005841.
PR 03-MAR-2000; 2000US-0187202P.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 05-JUN-2000; 2000US-0209832P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2001-408281/43.
DR N-PSDB; AAS21480.
XX
PT Isolated , secretory and transmembrane PRO polypeptide used to detect
PT other PRO polypeptides, link bioactive molecules to cells expressing PRO
PT polypeptides, and detect the presence of mammalian tumors e.g. lung,
PT breast, prostate, cervical.
XX
PS Claim 12; Fig 474; 813pp; English.
XX
CC AAU12172-AAU12446 represent novel human secretory and transmembrane PRO
CC polypeptides. The PRO polypeptides are useful to detect other PRO
CC polypeptides, to link bioactive molecules to cells expressing PRO
CC polypeptides, to modulate biological activities of cells expressing PRO
CC polypeptides, and to detect the presence of mammalian lung, colon,
CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
CC polypeptide expression in a cell sample to that in a control sample. Some
CC of the 275 sequences are also useful to stimulate the release of tumour
CC necrosis factor-alpha (TNF-alpha) from human blood, the proliferation or
CC differentiation of chondrocytes, the proliferation or gene expression in
CC pericyte cells, the release of proteoglycans from cartilage, the
CC proliferation of inner ear utricular supporting cells or of T-
CC lymphocytes, the release of a cytokine from peripheral blood monocytes
CC (PBMCs), or the proliferation of endothelial cells. Some of the PRO
CC polypeptides may modulate glucose or free fatty acid uptake by skeletal
CC muscle cells or by adipocytes; or inhibit binding of A-peptide to factor
CC VIIA. The PRO polypeptides can be used in assays to identify molecules
CC involved in binding interactions. The polynucleotides encoding PRO
CC polypeptides can be used to generate probes, antisense RNA/DNA,
CC transgenic or knock out animals and can be used in gene therapy
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 4; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 4
AAB50922
ID AAB50922 standard; protein; 90 AA.
XX
AC AAB50922;
XX
DT 21-MAR-2001 (first entry)
XX
DE Human PRO1159 protein.
XX
KW Human; PRO; antiinflammatory; dermatological; antiarthritic;
KW antirheumatic; cardiant; antianaemic; immunosuppressive; antithyroid;
KW antidiabetic; nootropic; neuroprotective; hepatotropic; virucide;
KW antiallergic; antiasthmatic; immune related disorder;
KW hepatobiliary disease; autoimmune disease; allergy.
XX
OS Homo sapiens.
XX
PN WO200073452-A2.
XX
PD 07-DEC-2000.
XX
PF 02-JUN-2000; 2000WO-US015264.
XX
PR 02-JUN-1999; 99WO-US012252.
PR 20-JUL-1999; 99US-0144732P.
PR 20-JUL-1999; 99US-0144758P.
PR 28-JUL-1999; 99US-0146222P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.

```
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028565.
PR   09-DEC-1999;   99US-0170262P.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005841.
PR   03-MAR-2000; 2000US-0187202P.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Chan B,  Goddard A,  Godowski PJ;
PI   Gurney AL,  Hebert C,  Henzel W,  Kabakoff RC,  Shelton DL,  Tumas D;
PI   Watanabe CK,  Wood WI;
XX
DR   WPI; 2001-025253/03.
DR   N-PSDB; AAC91481.
XX
PT   Thirty three nucleic acids encoding PRO polypeptides which are useful in
PT   the diagnosis and treatment of immune related disorders, e.g. systemic
PT   lupus erythematosis, rheumatoid arthritis, osteoarthritis, thyroiditis
PT   and diabetes mellitus.
XX
PS   Claim 58; Fig 42; 218pp; English.
XX
CC   The present sequence is one of thirty three novel PRO polypeptides. The
CC   PRO polypeptides, anti-PRO antibodies, agonists and antagonists are
CC   useful for treating and diagnosing immune related disorders such as
CC   systemic lupus erythematosus, rheumatoid arthritis, osteoarthritis,
CC   juvenile chronic arthritis, spondyloarthropathies, systemic sclerosis,
CC   idiopathic inflammatory myopathies, Sjogren's syndrome, systemic
CC   vasculitis, sarcoidosis, autoimmune haemolytic anaemia, autoimmune
CC   thrombocytopaenia, thyroiditis, diabetes mellitus, immune-mediated renal
CC   disease, demyelinating diseases of the central and peripheral nervous
CC   systems (such as multiple sclerosis, idiopathic demyelinating
CC   polyneuropathy or Guillain-Barre syndrome, and chronic inflammatory
CC   demyelinating polyneuropathy), hepatobiliary diseases (such as
CC   infectious, autoimmune chronic active hepatitis, primary biliary
CC   cirrhosis, granulomatous hepatitis and sclerosing cholangitis),
CC   inflammatory bowel disease, gluten-sensitive enteropathy and Whipple's
CC   disease, autoimmune or immune-mediated skin diseases (such as bullous
CC   skin diseases, erythema multiforme, contact dermatitis, psoriasis),
CC   allergic diseases such as asthma, allergic rhinitis, atopic dermatitis,
CC   food hypersensitivity and urticaria), immunological diseases of the lung
CC   (such as eosinophilic pneumonias, idiopathic pulmonary fibrosis and
CC   hypersensitivity pneumonitis), transplantation associated diseases
CC   including graft rejection and graft-versus-host diseases
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 4;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 5
AAB65271
ID   AAB65271 standard; protein; 90 AA.
XX
AC   AAB65271;
XX
DT   02-APR-2001  (first entry)
XX
DE   Human PRO1159 (UNQ589) protein sequence SEQ ID NO:377.
XX
KW   Human; secreted and transmembrane protein; PRO; cytostatic; cell death;
KW   cancer; chromosomal mapping; gene mapping; tissue typing;
KW   diagnostic assay.
XX
OS   Homo sapiens.
XX
PN   WO200073454-A1.
XX
PD   07-DEC-2000.
XX
PF   30-MAR-2000; 2000WO-US008439.
XX
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi CJ,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2001-032160/04.
DR   N-PSDB; AAF44240.
XX
PT   PRO polynucleotides used to produce polypeptides used to target bioactive
PT   molecules such as toxins, radiolabels or antibodies, to specific cells,
PT   to cause targeted cell death.
XX
PS   Claim 12; Fig 272; 935pp; English.
XX
CC   The present invention describes human secreted and transmembrane PRO
CC   proteins. The PRO proteins have cytostatic activity. The PRO proteins can
CC   be used for targeted delivery of bioactive molecules, such as toxins,
CC   radiolabels or antibodies, that cause cell death. PRO nucleotide
CC   sequences, and their fragments, can be used as hybridisation probes, in
```

```
CC   chromosomal and gene mapping, and in the generation of anti-sense RNA and
CC   DNA. They may also be used to produce transgenic animals which are used
CC   to develop and screen therapeutically useful reagents. The PRO nucleotide
CC   and protein sequence can be used for tissue typing and in treating
CC   cancer. Anti-PRO antibodies can be used in diagnostic assays. AAF44270 to
CC   AAF44470 represent PCR primers and hybridisation probes used in the
CC   isolation of human PRO sequences. AAF44087 to AAF44269 and AAB65154 to
CC   AAB65300 represent human PRO polynucleotide and protein sequences given
CC   in the exemplification of the present invention
XX
SQ   Sequence 90 AA;

  Query Match           100.0%;  Score 462;  DB 4;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 6
ABU58086
ID   ABU58086 standard; protein; 90 AA.
XX
AC   ABU58086;
XX
DT   14-APR-2003  (first entry)
XX
DE   Human PRO polypeptide #118.
XX
KW   Human; PRO; cytostatic; tumour; cancer; breast; lung; stomach; liver;
KW   horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT;
KW   antibody-dependent enzyme mediated prodrug therapy.
XX
OS   Homo sapiens.
XX
PN   US2003027163-A1.
XX
PD   06-FEB-2003.
XX
PF   15-NOV-2001; 2001US-00997666.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
```

PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 7
ABU59164
ID ABU59164 standard; protein; 90 AA.
XX
AC ABU59164;
XX
DT 28-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO1159.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2002132252-A1.
XX
PD 19-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00990442.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.

PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-247083/24.
DR N-PSDB; ABX80363.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT are therapeutically useful for enhancing immune response and in cancer
PT treatments.
XX
PS Claim 12; Fig 272; 648pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This is the
CC amino acid sequence of a novel human PRO protein
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 8
ABU82676
ID ABU82676 standard; protein; 90 AA.
XX
AC ABU82676;
XX
DT 26-JUN-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW Human; PRO; secreted protein; transmembrane protein;

KW cardiac insufficiency disorders; angiogenesis; wound healing;
KW cancerous tumour; immune response; retinal disorder; sight loss;
KW retinitis pigmentosum; age-related macular degeneration; AMD;
KW kidney disorder; Berger disease; nephropathy; dermatitis; herpetiformis;
KW Crohn's disease; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003032023-A1.
XX
PD 13-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990711.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.

PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 9
ABO17852
ID ABO17852 standard; protein; 90 AA.
XX
AC ABO17852;
XX
DT 26-AUG-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; antiinflammatory;
KW antiarteriosclerotic; cardiant; anti-infertility; anti-HIV; cytostatic;
KW antidiabetic; gene therapy; tumour necrosis factor (TNF)-alpha release;
KW TNF-alpha release; cell proliferation; cell differentiation;
KW gene expression modulator; proteoglycan release; cytokine release;
KW tumour; inflammatory disease; organ failure; atherosclerosis;
KW cardiac injury; infertility; birth defect; premature aging; AIDS;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW chromosome mapping; gene mapping; pharmaceutical; diagnostic; biosensor;
KW bioreactor; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003032156-A1.
XX
PD 13-FEB-2003.
XX
PF 06-MAY-2002; 2002US-00140474.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.

PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-341980/32.
DR N-PSDB; ACD24089.
XX
PT New secreted and transmembrane PRO nucleic acids, for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, axquired immunodeficiency
PT syndrome (AIDS), or cancer.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention describes an isolated nucleic acid (I) comprising, or which
CC has 80 % sequence identity to, or the full-length coding sequence of, one
CC of 275 nucleotide sequences, and which encodes a corresponding
CC polypeptide selected from 275 amino acid sequences, where all sequences
CC are given in the specification. The polypeptide encoded by (I) is used to
CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulate a biological activity of a cell, stimulate the
CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate
CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit
CC the proliferation or differentiation of cells or gene expression,
CC stimulate the release of proteoglycans, stimulate the release of cytokine
CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide
CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic
CC acid and polypeptide encoded by it, are useful for treating inflammatory
CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,
CC birth defects, premature aging, acquired immunodeficiency syndrome
CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as
CC hybridisation probes, in chromosome and gene mapping, and in generating
CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,
CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.
CC This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 10
ABU60595
ID ABU60595 standard; protein; 90 AA.
XX
AC ABU60595;
XX
DT 01-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #154.
XX
KW Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
KW diagnostic; therapeutic; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002160384-A1.
XX
PD 31-OCT-2002.
XX
PF 14-NOV-2001; 2001US-00992598.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.

PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-288106/28.
DR N-PSDB; ABX90341.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 12; Fig 272; 650pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful in gene therapy, in chromosome
CC identification, as chromosome markers, or in generating probes. The PRO
CC polypeptides are useful as molecular markers for protein electrophoresis,
CC and the isolated nucleic acids may be used for recombinantly expressing
CC those markers. The PRO polypeptides and nucleic acids may also be used in
CC tissue typing. Anti-PRO antibodies are useful in diagnostic assays for
CC PRO, and in affinity purification of PRO from recombinant cell culture or
CC natural sources. The sequences presented in ABU60478-ABU60624 are the PRO
CC polynucleotides of the invention. Note: The sequence data for this patent
CC is also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 11
ABU13977
ID ABU13977 standard; protein; 90 AA.
XX
AC ABU13977;
XX
DT 26-FEB-2003 (first entry)
XX
DE Human PRO1159 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
XX
OS Homo sapiens.
XX
PN US2002103125-A1.
XX
PD 01-AUG-2002.
XX
PF 20-NOV-2001; 2001US-00989731.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH LTD.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-102117/09.
DR N-PSDB; ABX64187.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 272; 649pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The polynucleotide sequences
CC encoding PRO polypeptides are useful as hybridisation probes, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC in the preparation of PRO polypeptides, for generating transgenic animals
CC or knockout animals, to construct hybridisation probes for mapping the
CC gene which encodes the PRO polypeptide, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, as chromosome markers, and for generating probes for PCR,
CC Northern analysis, Southern analysis and Western analysis. ABU13860-
CC ABU14006 represent the human PRO polypeptides of the invention. Note: The
CC sequence data for this patent was obtained in electronic format directly
CC from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 12
ABU81106
ID ABU81106 standard; protein; 90 AA.
XX
AC ABU81106;
XX
DT 23-JUN-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;

KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;
KW bone disorder; cartilage disorder; rheumatoid arthritis; obesity;
KW sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;
KW hearing loss; coagulation disorder; stroke; heart attack; cardiant;
KW antidiabetic; anorectic; vulnerary; antiarthritic; osteopathic;
KW antirheumatic; auditory; cerebroprotective; angiogenic.
XX
OS Homo sapiens.
XX
PN US2003004311-A1.
XX
PD 02-JAN-2003.
XX
PF 19-DEC-2001; 2001US-00028072.
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.
PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-352836/33.
DR N-PSDB; ACA67230.
XX
PT New isolated PRO polypeptide useful for treating diabetes, rheumatoid
PT arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or
PT heart attack.
XX
PS Claim 12; Fig 474; 643pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides and polynucleotides are useful for preparing a medicament
CC useful in the treatment of diabetes, bone and/or cartilage disorders
CC (e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,
CC hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders
CC (e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic
CC assays for PRO, by detecting its expression in specific cells, tissues or
CC serum, and for affinity purification of PRO from recombinant cell culture
CC or natural sources. ABU80870-ABU81144 represent the human PRO
CC polypeptides of the invention. Note: The sequence data for this patent
CC was obtained in electronic format directly from the USPTO web site at
CC seqdata.uspto.gov/psipsDIDEntry.html
XX

```
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 13
ABU72562
ID   ABU72562 standard; protein; 90 AA.
XX
AC   ABU72562;
XX
DT   17-JUN-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; cytostatic; anti-HIV;
KW   virucide; hepatotropic; antiinflammatory; neuroprotective; gene therapy;
KW   PRO; pharmaceutical; diagnostic; biosensor; bioreactor; malignancy;
KW   cancer; ovarian cancer; colorectal cancer; Kaposi's sarcoma; leukaemia;
KW   lymphoma; hepatitis B; multiple sclerosis; Crohn's disease;
KW   drug screening.
XX
OS   Homo sapiens.
XX
PN   US2003003531-A1.
XX
PD   02-JAN-2003.
XX
PF   19-NOV-2001; 2001US-00989734.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-352829/33.
DR   N-PSDB; ACA64409.
XX
PT   New genes and secreted and transmembrane polypeptides (e.g. PRO183 or
```

PT PRO184), useful for treating or diagnosing e.g. ovarian cancer, Kaposi's
PT sarcoma, leukemia, lymphoma, hepatitis B, multiple sclerosis or Crohn's
PT disease.
XX
PS Claim 12; Fig 272; 663pp; English.
XX
CC The invention describes a new isolated nucleic acid molecule comprising
CC the full length coding sequence of the DNA deposited with the American
CC Type Culture Collection (e.g. ATCC Deposit No. 209621, 552-PTA, 819-PTA,
CC 209439, 203135, etc); or a sequence with at least 80% identity to a DNA
CC encoding a PRO polypeptide. The PRO polypeptides or polynucleotides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. These
CC are particularly useful for detecting or treating e.g. malignancies or
CC cancers (e.g. ovarian cancer, colorectal cancer, Kaposi's sarcoma,
CC leukaemia or lymphoma), hepatitis B, multiple sclerosis, or Crohn's
CC disease in mammals. The PRO polypeptides are useful in drug screening,
CC particularly as targets for therapeutic intervention in these diseases,
CC and in the diagnostic determination of the presence of these diseases.
CC The PRO polypeptides are also useful as molecular weight markers, or for
CC chromosome identification. The PRO genes are useful as hybridisation
CC probes, or for screening libraries of human cDNA, genomic DNA or mRNA.
CC The PRO genes may also be used in gene therapy, particularly for
CC replacing a defective gene. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO polypeptide
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 14
ABU66806
ID ABU66806 standard; protein; 90 AA.
XX
AC ABU66806;
XX
DT 23-MAY-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO polypeptide; secreted and transmembrane protein;
KW tumour necrosis factor-alpha; TNF-alpha; blood; proliferation;
KW differentiation; chondrocyte; tumour; genetic disorder; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003036180-A1.
XX
PD 20-FEB-2003.
XX
PF 09-MAY-2002; 2002US-00143114.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.

PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-332040/31.
DR N-PSDB; ACA03839.
XX
PT New secreted and transmembrane PRO nucleic acids, useful for gene
PT therapy, in chromosome and gene mapping, as chromosome markers, in tissue
PT typing, and in chromosome identification.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The PRO polypeptides are useful for
CC for stimulating the release of tumour necrosis factor (TNF)-alpha from
CC human blood, for stimulating the proliferation or differentiation of
CC chondrocytes, and detecting the presence of tumours. The polynucleotide
CC sequences encoding PRO polypeptides are useful as hybridisation probes,
CC in chromosome and gene mapping, in the generation of antisense RNA and
CC DNA, in the preparation of PRO polypeptides, for generating transgenic
CC animals or knockout animals, for the genetic analysis of individuals with
CC genetic disorders, and in gene therapy. ABU66570-ABU66844 represent the
CC human PRO polypeptides of the invention. Note: The sequence data for this
CC patent was obtained in electronic format directly from the USPTO web site
CC at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 15
ABU59887
ID ABU59887 standard; protein; 90 AA.
XX
AC ABU59887;
XX
DT 13-MAY-2003 (first entry)
XX
DE Novel secreted and transmembrane protein PRO1159.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003017563-A1.
XX
PD 23-JAN-2003.
XX
PF 07-MAY-2002; 2002US-00140808.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.

PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-148238/14.
DR N-PSDB; ABX89377.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention describes an isolated human PRO polypeptide. The PRO
CC polypeptides are useful in detecting PRO polypeptides in a sample, in
CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
CC in modulating at least one biological activity of a cell expressing a PRO
CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186
CC stimulate adrenal cortical capillary endothelial growth, and PRO536,
CC PRO943, PRO828, PRO826, PRO1068 or PRO535, PRO826, PRO819, PRO1126,
CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
CC useful for treating conditions or disorders where angiogenesis would be
CC beneficial, e.g. wound healing and antagonist of this polypeptide are
CC useful for treating cancerous tumours. PRO812 inhibits vascular
CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
CC cells and is thus useful for inhibiting endothelial cell growth in
CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
CC stimulated T-lymphocytes and are therapeutically useful for enhancing
CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
CC rod photoreceptor cells) and therefore are useful for treating retinal
CC disorders of injuries, e.g. retinitis pigmentosum, AMD. PRO819, PRO813
CC and PRO11066 induce proliferation of mammalian kidney mesangial cells,
CC and therefore are useful for treating kidney disorders associated with
CC decreased mesangial cell function such as Berger disease or other
CC nephropathies associated with dermatitis, herpetiformis or Crohn's
CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
CC proliferation and/or redifferentiation of chondrocytes in culture and are
CC thus useful for treating sports injuries, and arthritis. This is the
CC amino acid sequence of a novel human PRO protein
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 16
ABU59311
ID ABU59311 standard; protein; 90 AA.
XX
AC ABU59311;
XX
DT 22-APR-2003 (first entry)
XX
DE Human secreted/transmembrane protein, #154.
XX
KW Human; PRO; secreted; transmembrane; pharmaceutical; diagnostic;
KW biosensor; bioreactor; tumour; therapeutic; gene therapy;
KW tumour-associated antigenic target; TAT; ADEPT;
KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003027162-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-00997428.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 17
ABO26008
ID ABO26008 standard; protein; 90 AA.
XX
AC ABO26008;
XX
DT 10-SEP-2003 (first entry)
XX
DE Human PRO1159 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW genetic disorder; antibacterial; immunosuppressive.
XX
OS Homo sapiens.
XX
PN US2002127576-A1.
XX
PD 12-SEP-2002.
XX
PF 14-NOV-2001; 2001US-00991073.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.

XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-340824/32.
DR N-PSDB; ACD44377.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT and are therapeutically useful for enhancing immune responses.
XX
PS Claim 12; Fig 272; 661pp; English.
XX
CC The present invention relates to the isolation of novel human PRO
CC polypeptides, and the polynucleotide sequences encoding them. The PRO
CC polypeptides are secreted and transmembrane proteins. The PRO
CC polypeptides are useful for detecting other PRO polypeptides, for linking
CC bioactive molecules to cells expressing PRO polypeptides, for modulating
CC biological activities of cells expressing PRO polypeptides, and for for
CC identifying agonists or antagonists. The polynucleotide sequences
CC encoding PRO polypeptides are useful as hybridisation probes, in
CC chromosome and gene mapping, in the generation of antisense RNA and DNA,
CC in the preparation of PRO polypeptides, for generating transgenic animals
CC or knockout animals, to construct hybridisation probes for mapping the
CC gene which encodes the PRO polypeptide, and for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, as chromosome markers, and for generating probes for PCR,
CC Northern analysis, Southern analysis and Western analysis. ABO25891-
CC ABO26037 represent the human PRO polypeptides of the invention. Note: The
CC sequence data for this patent was obtained in electronic format directly
CC from the USPTO web site at seqdata.uspto.gov/psipsDIDEntry.html
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 18
ABO25077
ID ABO25077 standard; protein; 90 AA.
XX
AC ABO25077;
XX
DT 05-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein (PRO) #237.
XX
KW Human; PRO; secreted protein; transmembrane protein; tumour; cytostatic;
KW gene therapy; tumour necrosis factor-alpha; TNF-alpha; blood;
KW proteoglycan; cartilage; cytokine; peripheral blood mononuclear cell;
KW PBMC; glucose uptake; FFA; skeletal muscle cell; adipocyte cell;
KW chondrocyte cell proliferation; chondrocyte cell differentiation;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell; A-peptide; factor VIIA.
XX
OS Homo sapiens.
XX
PN US2003036179-A1.
XX
PD 20-FEB-2003.
XX
PF 10-MAY-2002; 2002US-00142431.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-466355/44.
DR N-PSDB; ACD42031.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising at least 80%
CC sequence identity to a PRO (secreted and transmembrane protein) cDNA
CC comprising a nucleic acid (a) encoding a PRO polypeptide, or its
CC extracellular domain (with or without its associated signal peptide),
CC which comprises any of the 275 120-850 residue amino acid sequences,
CC given in the specification; (b) comprising any of the 275 300-3500
CC nucleotide sequences, given in the specification; or (c) comprising the
CC full-length coding sequence of the nucleotide sequences given in the
CC specification, or of the DNA deposited under any of the American Type
CC Culture Collection (ATCC) Accession Numbers listed in the specification.
CC Also included are a vector comprising the novel nucleic acid, a host cell
CC comprising the vector, producing a PRO polypeptide, the isolated PRO
CC polypeptides detailed above, a chimaeric molecule comprising the PRO
CC polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC antibody, detecting a PRO polypeptide in a sample suspected of containing
CC the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC PRO polypeptide, modulating at least one biological activity of a cell
CC expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC modulating the uptake of glucose or FFA by skeletal muscle cells or
CC adipocyte cells, stimulating the proliferation or differentiation of
CC chondrocyte cells (or proliferation of or gene expression in pericyte
CC cells), stimulating the proliferation of inner ear utricular supporting
CC cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC binding of A-peptide to factor VIIA, or differentiation of adipocyte
CC cells, detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences given
CC in the specification. The polynucleotide is useful in molecular biology,
CC including uses as hybridisation probes, in chromosome and gene mapping,
CC in generating antisense RNA and DNA, and in gene therapy. The
CC polynucleotide may also be used in preparing PRO polypeptides by
CC recombinant techniques, and in generating either transgenic animals or
CC knock-out animals which, in turn, are useful in the development and
CC screening of therapeutically useful reagents. The PRO polypeptide or the
CC antibody is used in preparing a medicament for treating a condition
CC responsive to the polypeptide or antibody, such as tumours, and in
CC various diagnostic assays. The present sequence rperesents a PRO
CC polypeptide
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 19
ABU59017
ID ABU59017 standard; protein; 90 AA.
XX
AC ABU59017;
XX
DT 16-APR-2003 (first entry)
XX
DE Human sectreted/transmembrane protein, #154.
XX
KW Human; PRO; secreted; transmembrane; signal peptide; pharmaceutical;
KW diagnostic; biosensor; bioreactor; tumour; therapeutic; colon cancer;
KW lung cancer; breast cancer; cancer; gene therapy.
XX
OS Homo sapiens.
XX
PN US2002142961-A1.
XX
PD 03-OCT-2002.
XX
PF 19-NOV-2001; 2001US-00989721.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.

```
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-155950/15.
XX
PT   New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
PT   PRO361 or PRO846) useful as targets for therapeutic intervention in
PT   cancers (e.g. lung or breast cancers), or for diagnosing these cancers.
XX
PS   Claim 12; Fig 272; 647pp; English.
XX
CC   The invention discloses isolated PRO secreted/transmembrane polypeptides
CC   comprising a sequence without signal peptide and the nucleic acid
CC   encoding them. The polypeptides can be used to raise antibodies that
CC   specifically bind to the PRO polypeptide, for linking a bioactive
CC   molecule to a cell expressing a PRO protein and for modulating at least
CC   one biological activity of a cell. The PRO polypeptides or
CC   polynucleotides are also useful as pharmaceuticals, diagnostics,
CC   biosensors or bioreactors, for detecting or treating e.g. tumours in
CC   mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
CC   rabbits as targets for therapeutic intervention in certain cancers (e.g.
CC   colon, lung or breast cancers) and diagnostic determination of the
CC   presence of these cancers. The PRO polypeptides are also useful as
CC   molecular weight markers or for chromosome identification. The PRO genes
CC   are useful as hybridisation probes or for screening libraries of human
CC   cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
CC   therapy, particularly for replacing a defective gene. The sequences
CC   presented in ABU58900-ABU59046 are the PRO polypeptides of the invention
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 20
ABU92395
ID   ABU92395 standard; protein; 90 AA.
XX
AC   ABU92395;
XX
DT   16-JUL-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO; PRO183; PRO184; PRO185;
KW   PRO943; PRO1133; PRO331; PRO1387; PRO363; PRO5723; PRO1114; PRO3301;
KW   PRO9940; PRO1181; PRO7170; PRO361; PRO846; bioactive molecule; toxin;
KW   radiolabel; antibody; cell death; tissue typing; gene therapy;
KW   cytostatic; chromosome mapping; gene mapping; transgenic animal;
KW   knockout animal; immunohistochemical staining.
XX
OS   Homo sapiens.
XX
PN   US2003022187-A1.
XX
PD   30-JAN-2003.
XX
PF   14-NOV-2001; 2001US-00993667.
XX
```

PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 22-JUN-1998; 98US-0090282P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.

PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 21
ABU59460
ID ABU59460 standard; protein; 90 AA.
XX
AC ABU59460;
XX
DT 22-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO1124.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosum; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpetiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis.
XX
OS Homo sapiens.
XX
PN US2003027985-A1.
XX
PD 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990562.

XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.

PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 22
ABU67082
ID ABU67082 standard; protein; 90 AA.
XX
AC ABU67082;
XX
DT 27-MAY-2003 (first entry)
XX
DE Human secreted/transmembrane, PRO, protein SEQ ID 474.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW infertility; birth defects; premature aging; AIDS; biosensor;
KW acquired immunodeficiency syndrome; cancer; diabetic complication;
KW bioreactor; tumour.
XX
OS Homo sapiens.
XX
PN US2003032155-A1.
XX
PD 13-FEB-2003.
XX
PF 03-MAY-2002; 2002US-00137865.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-331925/31.
DR N-PSDB; ACA04260.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising, or which is
CC at least 80% identical to, or the full-length coding sequence of, any of
CC the 275 nucleotide sequences, encoding the corresponding PRO polypeptide
CC (one of 275 secreted or transmembrane proteins). The nucleic acid further
CC comprises the full-length coding sequence of the DNA deposited under
CC American Type Culture Collection (ATCC) accession number in a list given
CC in the specification. Also included are vectors and host cells for
CC producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO
CC extracellular domains and mature sequences, methods of detecting PRO
CC proteins, methods for stimulating the release of TNF-alpha (tumour
CC necrosis factor alpha) from human blood, (and the proliferation of
CC differentiation of chondrocyte cells, the proliferation of, or gene
CC expression in pericyte cells, the release or proteoglycans from
CC cartilage, proliferation of inner ear urticular supporting cells, the
CC proliferation of T-lymphocyte cells, the release of a cytokine from
CC peripheral blood mononuclear cells (PBMC), or the proliferation of
CC endothelial cells), a method for modulating the uptake of glucose or free
CC fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the
CC binding of A-peptide to factor VIIA, or the differentiation of adipocyte
CC cells, a method for detecting the presence of a tumour in a mammal and an
CC oligonucleotide probe derived from any of the nucleotide sequences cited
CC above. The nucleic acids and polypeptides are useful for treating
CC inflammatory diseases, organ failure, atherosclerosis, cardiac injury,
CC infertility, birth defects, premature aging, AIDS (acquired
CC immunodeficiency syndrome), cancer, or diabetic complications. The
CC nucleic acids are useful as hybridisation probes, in chromosome and gene
CC mapping, and in generating antisense RNA or DNA. The polypeptides are
CC useful as pharmaceuticals, diagnostics, biosensors or bioreactors. Both
CC are useful in tissue typing. The present sequence represents a PRO
CC protein of the invention
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 23
ABU92226
ID ABU92226 standard; protein; 90 AA.
XX
AC ABU92226;
XX
DT 16-JUL-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003017476-A1.
XX
PD 23-JAN-2003.
XX
PF 20-NOV-2001; 2001US-00989724.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.

```
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 24
ABU10932
ID   ABU10932 standard; protein; 90 AA.
XX
AC   ABU10932;
XX
DT   04-FEB-2003  (first entry)
XX
DE   Human PRO polypeptide #118.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide; toxin;
KW   radiolabel; cell death; gene mapping; chromosome mapping;
KW   protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
KW   antibacterial.
XX
OS   Homo sapiens.
XX
PN   US2002123463-A1.
XX
PD   05-SEP-2002.
XX
PF   19-NOV-2001; 2001US-00989732.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
```

PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 06-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-066810/06.
DR N-PSDB; ABX17151.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 272; 655pp; English.
XX
CC The invention relates to a secreted and transmembrane polypeptide, termed
CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is
CC useful for detecting PRO polypeptides and for linking a bioactive
CC molecule to a cell expressing the above polypeptides, where the bioactive
CC molecule is a toxin, radiolabel or an antibody. The bioactive material
CC causes the death of the cell. The polypeptide is useful for identifying
CC agonists or antagonists of the PRO polypeptide, for preparing variants of
CC PRO, as a molecular weight marker for protein electrophoresis purposes
CC and the PRO polynucleotide is useful for recombinantly expressing those
CC markers. The polynucleotide is also useful as a hybridisation probe, in
CC chromosome and gene mapping, in generation of antisense RNA and DNA, in
CC the preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, to construct hybridisation
CC probes for mapping the gene which encodes PRO and for the genetic
CC analysis of individuals with genetic disorders, in gene therapy, for
CC chromosome identification, as a chromosome marker and for generating
CC probes for PCR, Northern analysis, Southern analysis and Western
CC analysis. This sequence represents a human PRO polypeptide of the
CC invention
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 25
ABU81684
ID ABU81684 standard; protein; 90 AA.
XX
AC ABU81684;
XX
DT 24-JUN-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; gene therapy; PRO; PRO943;
KW PRO183; PRO184; PRO185; PRO331; PRO1133; PRO363; PRO5723; PRO1387;
KW PRO1114; PRO3301; PRO9940; PRO1181; PRO7170; PRO361; PRO846;
KW bioactive molecule; toxin; radiolabel; antibody; cell death; cancer;
KW autoimmune disease; chromosome mapping; gene mapping; transgenic animal;
KW knockout animal; septic shock.
XX
OS Homo sapiens.
XX
PN US2002177164-A1.
XX
PD 28-NOV-2002.
XX
PF 20-NOV-2001; 2001US-00989293.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-328481/31.
DR N-PSDB; ACA68006.
XX
PT New secreted and transmembrane polypeptide, useful for modulating
PT biological activity of cell expressing the polypeptide, for identifying
PT agonists or antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 272; 654pp; English.
XX
CC The invention describes an isolated, secreted and transmembrane
CC polypeptide (I), termed PRO polypeptide. (I) is useful for detecting
CC PRO943, PRO183, PRO184, PRO185, PRO331, PRO1133, PRO363, PRO5723,
CC PRO1387, PRO1114, PRO3301, PRO9940, PRO1181, PRO7170, PRO361 or PRO846
CC polypeptide comprising contacting the sample with the polypeptide and
CC determining formation of a polypeptide conjugate. (I) is also useful for
CC linking a bioactive molecule e.g. toxin, radiolabel or antibody, to a
CC cell expressing the above polypeptides to cause cell death. (I) is also
CC useful as a therapeutic agent e.g. for treating cancer and autoimmune
CC disease. PRO is useful in assays to identify other proteins or molecules
CC involved in binding interactions. The polynucleotide (II) encoding (I) is
CC useful in chromosome and gene mapping, for generating transgenic animals
CC or knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, for the genetic analysis of
CC individuals with genetic disorders, in gene therapy, for chromosome
CC identification, and as a chromosome marker. An anti-(I)-antibody is
CC useful in diagnostic assays for PRO, e.g. detecting its expression in
CC specific cells, tissues or serum, for affinity purification of PRO, and
CC for treating septic shock. This is the amino acid sequence of a novel
CC human secreted and transmembrane PRO polypeptide
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 26
ABU88623
ID ABU88623 standard; protein; 90 AA.
XX
AC ABU88623;
XX
DT 11-AUG-2003 (first entry)
XX
DE Human secreted and transmembrane polypeptide PRO1159.
XX
KW Human; gene therapy; cancer; retinal disorder; wound healing;
KW kidney disorder.
XX
OS Homo sapiens.
XX
PN US2002197615-A1.
XX

PD 26-DEC-2002.
XX
PF 16-NOV-2001; 2001US-00991181.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-370792/35.
DR N-PSDB; ACA88455.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for the preparation of a medicament for treating a
PT condition that is responsive to the PRO polypeptide. e.g., cancer.
XX
PS Claim 12; Fig 272; 647pp; English.
XX
CC The invention relates to an isolated nucleic acid encoding a PRO
CC polypeptide. The polypeptide, agonist, antagonist and antibody are useful
CC for the preparation of a medicament for treating a condition that is
CC responsive to the PRO polypeptide. The nucleotide sequence is useful in
CC molecular biology including being used as hybridisation probes, in
CC chromosome and gene mapping and in the generation of anti-sense RNA and
CC DNA. The PRO polypeptides can also be used in the treatment of e.g.
CC cancer, retinal disorders, wound healing and kidney disorders. The
CC present sequence represents the amino acid sequence of a human secreted
CC and transmembrane PRO polypeptide of the present invention. Note: The
CC sequence data for this patent did not form part of the printed
CC specification but was obtained in electronic format directly from USPTO
CC at seqdata.uspto.gov/sequence.html?DocID=20020197615
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 27
ABO34137

ID ABO34137 standard; protein; 90 AA.
XX
AC ABO34137;
XX
DT 19-SEP-2003 (first entry)
XX
DE Human PRO1159 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW biosensor; bioreactor; tumour; cancer; diabetes; ALS; ulcer;
KW rheumatoid arthritis; amyotrophic lateral sclerosis; cytostatic;
KW antidiabetic; antiarthritic; antirheumatic; antiulcer.
XX
OS Homo sapiens.
XX
PN US2003017981-A1.
XX
PD 23-JAN-2003.
XX
PF 20-NOV-2001; 2001US-00989728.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091633P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.

```
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   07-SEP-2000; 2000US-0230978P.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.

  Query Match           100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 28
ADA45993
ID   ADA45993 standard; protein; 90 AA.
XX
AC   ADA45993;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003022328-A1.
XX
PD   30-JAN-2003.
XX
PF   16-APR-2002; 2002US-00123904.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
```

PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-584997/55.
DR N-PSDB; ADA45992.
XX
PT Novel secreted and transmembrane polypeptide for modulating biological
PT activity of cell expressing the polypeptide, identifying agonists or
PT antagonists of polypeptide, and as molecular weight markers.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 29
ADA76424
ID ADA76424 standard; protein; 90 AA.
XX
AC ADA76424;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073212-A1.
XX
PD 17-APR-2003.
XX
PF 16-APR-2002; 2002US-00123903.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.

PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-687639/65.
DR N-PSDB; ADA76423.
XX
PT New isolated nucleic acid encoding a secreted and transmembrane
PT polypeptide, designated e.g. PRO1114 or PRO4978, useful in chromosome and
PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 30
ADA19074
ID ADA19074 standard; protein; 90 AA.
XX
AC ADA19074;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;
KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;
KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;
KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;
KW factor VIIA; endothelial cell.
XX
OS Homo sapiens.
XX
PN US2003054517-A1.
XX
PD 20-MAR-2003.
XX
PF 08-MAY-2002; 2002US-00141755.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-521854/49.
DR N-PSDB; ADA19073.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumors.

XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. lung, colon, breast,
CC prostate, rectal, cervical and liver tumours). The polynucleotides are
CC useful in molecular biology, including uses as hybridisation probes, in
CC chromosome and gene mapping, in generating antisense RNA and DNA and in
CC gene therapy. The polynucleotides may also be used in preparing PRO
CC polypeptides by recombinant techniques and in generating either
CC transgenic animals or knock-out animals which are useful in the
CC development and screening of therapeutically useful reagents. The PRO
CC polypeptides or antibodies are used in preparing a medicament for
CC treating a condition responsive to the polypeptides or antibodies, such
CC as tumours, for modulating the uptake of glucose or FFA by adipocyte
CC cells, for stimulating the proliferation of or gene expression in
CC pericyte cells, for stimulating the release of proteoglycans from
CC cartilage, for stimulating the proliferation of inner ear utricular
CC supporting cells, for stimulating the release of cytokines from PBMC
CC cells, for inhibiting the binding of A-peptide to factor VIIA, for
CC inhibiting the differentiation of adipocyte cells and for stimulating the
CC proliferation of endothelial cells. This sequence represents a human PRO
CC polypeptide of the invention. Note: The sequence data for this patent is
CC also available in electronic format from USPTO at
CC seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 31
ADA61697
ID ADA61697 standard; protein; 90 AA.
XX
AC ADA61697;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO1159.
XX

PN US2003049816-A1.
XX
PD 13-MAR-2003.
XX
PF 15-APR-2002; 2002US-00123262.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.

PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695892/66.
DR N-PSDB; ADA61696.
XX
PT New PRO nucleic acid and encode polypeptides, are useful for
PT manufacturing a medicament for diagnosing or treating cancer.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

```
  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 32
ADB19482
ID ADB19482 standard; protein; 90 AA.
XX
AC ADB19482;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine releas.
XX
OS Homo sapiens.
XX
PN US2003068796-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123261.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.

```
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-695927/66.
DR   N-PSDB; ADB19481.
XX
PT   Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT   the release of tumor necrosis factor alpha and detecting the presence of
PT   a tumor in a mammal.
XX
PS   Claim 12; Fig 474; 660pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 33
ADB28023
ID   ADB28023 standard; protein; 90 AA.
XX
AC   ADB28023;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082704-A1.
XX
PD   01-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131819.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-765415/72.
DR   N-PSDB; ADB28022.
```

XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 34
ADA86502
ID ADA86502 standard; protein; 90 AA.
XX
AC ADA86502;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082711-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147508.
XX
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUN-1999; 99WO-US012252.
PR 07-JUL-1999; 99US-0143048P.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786914/74.
DR N-PSDB; ADA86501.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

```
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 35
ADB16066
ID   ADB16066 standard; protein; 90 AA.
XX
AC   ADB16066;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003087350-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127821.
XX
PR   04-AUG-1998;   98US-0095301P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-786941/74.
DR   N-PSDB; ADB16065.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 36
ADA37888
ID   ADA37888 standard; protein; 90 AA.
XX
AC   ADA37888;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1159.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   c-fos induction; adipocyte cell; chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer;
KW   rod photoreceptor cell.
XX
OS   Homo sapiens.
XX
PN   US2003008297-A1.
XX
PD   09-JAN-2003.
XX
PF   15-NOV-2001; 2001US-00997653.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
```

PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-531419/50.
DR N-PSDB; ADA37887.
XX
PT New isolated PRO183, PRO184, PRO361 or PRO846 nucleic acid and secreted
PT transmembrane polypeptides, useful as targets for the diagnosis and
PT treatment of cancers, such as lung and breast cancers.
XX
PS Claim 12; Fig 272; 660pp; English.
XX
CC The invention relates to an isolated nucleic acid molecule comprising the
CC full-length coding sequence of the DNA ATCC Accession Numbers given in
CC the specification, or comprising a sequence with at least 80% identity
CC to: (a) a nucleotide encoding any of 147 PRO polypeptides, or an
CC extracellular domain of the polypeptide; or (b) any of 147 nucleotide
CC sequences fully defined in the specification. Also included are the PRO
CC proteins (or their extracellular domains with or without their associated
CC extracellular domains), expression vectors, host cells, PRO chimaeric
CC proteins, anti-PRO antibodies, methods of detecting polypeptide in a
CC sample, methods of linking a bioactive molecule to a cell expressing a
CC polypeptide and methods of modulating at least one biological activity of
CC a cell expressing the polypeptide. The PRO polypeptides or
CC polynucleotides are useful as pharmaceuticals, diagnostics, biosensors or
CC bioreactors. These are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocyte
CC cells, inducing proliferation and/or re-differentiation of chondrocytes,
CC or inducing pancreatic beta-cell precursor differentiation. In
CC particular, these are useful for detecting or treating tumours and
CC certain cancers (colon, lung or breast cancers) in mammals, e.g. humans,
CC dogs, cats, cattle, horses, sheep, pigs, goats, or rabbits. The PRO genes
CC may also be used in gene therapy, particularly for replacing a defective
CC gene. The present sequence represents a PRO protein.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 37
ADA47852
ID ADA47852 standard; protein; 90 AA.
XX
AC ADA47852;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX

KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073215-A1.
XX
PD 17-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140925.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-644801/61.
DR N-PSDB; ADA47851.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 38
ADA21574
ID ADA21574 standard; protein; 90 AA.
XX
AC ADA21574;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane polypeptide PRO1159.
XX
KW human; tumour; cancer; colorectal cancer; gene therapy;
KW chondrocyte differentiation; VEGF inhibition;
KW vascular endothelial growth factor; Alzheimer's disease;
KW Parkinson's disease; atherosclerosis; cystic fibrosis;
KW multiple sclerosis; ovarian cancer; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003054404-A1.
XX
PD 20-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997601.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.

PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 39
ADA10361
ID ADA10361 standard; protein; 90 AA.
XX
AC ADA10361;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein, PRO1159.
XX
KW PRO; secreted protein; transmembrane protein; human; septic shock;
KW immunogen.
XX
OS Homo sapiens.
XX
PN US2003059831-A1.
XX
PD 27-MAR-2003.
XX
PF 19-NOV-2001; 2001US-00989729.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.

PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 40
ADA67647
ID ADA67647 standard; protein; 90 AA.
XX
AC ADA67647;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068795-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123236.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.

PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695926/66.
DR N-PSDB; ADA67646.
XX
PT Novel isolated PRO secreted and transmembrane polypeptides useful for
PT stimulating the release of tumor necrosis factor-alpha from human blood
PT and detecting the presence of a tumor in a mammal.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 41
ADB30654
ID ADB30654 standard; protein; 90 AA.
XX
AC ADB30654;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068794-A1.
XX
PD 10-APR-2003.
XX
PF 15-APR-2002; 2002US-00123155.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-708391/67.
DR N-PSDB; ADB30653.
XX
PT New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 42
ADA85950
ID ADA85950 standard; protein; 90 AA.
XX
AC ADA85950;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.

XX
PN US2003082693-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127843.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786907/74.
DR N-PSDB; ADA85949.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 43
ADA17905
ID ADA17905 standard; protein; 90 AA.

XX
AC ADA17905;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO1159 polypeptide.
XX
KW Human; PRO polypeptide; secreted protein; transmembrane protein;
KW transgenic; tumour; cytostatic.
XX
OS Homo sapiens.
XX
PN US2003054987-A1.
XX
PD 20-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990443.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.

PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 44
ADA97162
ID ADA97162 standard; protein; 90 AA.
XX
AC ADA97162;
XX

DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082705-A1.
XX
PD 01-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131829.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755112/71.
DR N-PSDB; ADA97161.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 45
ADA79466
ID ADA79466 standard; protein; 90 AA.
XX
AC ADA79466;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082763-A1.
XX
PD 01-MAY-2003.
XX
PF 17-APR-2002; 2002US-00124818.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX

PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755116/71.
DR N-PSDB; ADA79465.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in detection and treatment of cancer and in modulating the uptake of
PT glucose or free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 46
ADA87605
ID ADA87605 standard; protein; 90 AA.
XX
AC ADA87605;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.

XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087345-A1.
XX
PD 08-MAY-2003.
XX
PF 16-APR-2002; 2002US-00123907.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786937/74.
DR N-PSDB; ADA87604.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes

```
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 47
ADB16807
ID   ADB16807 standard; protein; 90 AA.
XX
AC   ADB16807;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003087349-A1.
XX
PD   08-MAY-2003.
XX
PF   19-APR-2002; 2002US-00125928.
XX
PR   19-JUN-1998;   98US-0089947P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   02-MAR-2000; 2000WO-US005841.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786940/74.
DR   N-PSDB; ADB16806.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 48
ADA28013
ID   ADA28013 standard; protein; 90 AA.
XX
AC   ADA28013;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1159.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   rod photoreceptor cell; c-fos induction; adipocyte cell;
KW   chondrocyte differentiation;
```

KW pancreatic beta-cell precursor differentiation;
KW cardiac insufficiency disorder; wound; cancerous tumour;
KW retinal disorders; loss of sight; retinitis pigmentosum; kidney disorder;
KW obesity; diabetes; hyperinsulinaemia; hypoinsulinaemia; bone disorder;
KW cartilage disorder; sports injury; arthritis; cancer; human.
XX
OS Homo sapiens.
XX
PN US2003054359-A1.
XX
PD 20-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990726.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.

```
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.

  Query Match           100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 49
ADA91899
ID   ADA91899 standard; protein; 90 AA.
XX
AC   ADA91899;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082694-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127845.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786908/74.
DR   N-PSDB; ADA91898.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT   or a composition for treating e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match           100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 50
ADB14962
```

ID ADB14962 standard; protein; 90 AA.
XX
AC ADB14962;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087351-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127822.
XX
PR 17-JUN-1998; 98US-0089532P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786942/74.
DR N-PSDB; ADB14961.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 51
ADB18923
ID ADB18923 standard; protein; 90 AA.
XX
AC ADB18923;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine releas.
XX
OS Homo sapiens.
XX
PN US2003073211-A1.
XX
PD 17-APR-2003.
XX
PF 15-APR-2002; 2002US-00123292.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695954/66.
DR N-PSDB; ADB18922.
XX
PT New isolated nucleic acid and encoded PRO polypeptide, are useful in the
PT diagnosis and treatment of cancer.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyt
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 52
ADA94138
ID ADA94138 standard; protein; 90 AA.
XX
AC ADA94138;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077722-A1.
XX
PD 24-APR-2003.
XX
PF 03-MAY-2002; 2002US-00137872.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755077/71.
DR N-PSDB; ADA94137.
XX
PT New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT breast, prostate, rectal, cervical and/or liver tumors.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 53
ADB20034
ID ADB20034 standard; protein; 90 AA.
XX
AC ADB20034;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082691-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127838.
XX
PR 17-NOV-1998; 98US-0108802P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755108/71.
DR N-PSDB; ADB20033.
XX
PT PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 54
ADB13346
ID ADB13346 standard; protein; 90 AA.
XX
AC ADB13346;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082710-A1.
XX
PD 01-MAY-2003.
XX
PF 16-MAY-2002; 2002US-00147484.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786913/74.
DR N-PSDB; ADB13345.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT preparing a composition for treating e.g., tumor, or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 55
ABO43385
ID ABO43385 standard; protein; 90 AA.
XX
AC ABO43385;
XX
DT 26-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy;
KW chromosome identification; tissue typing.
XX
OS Homo sapiens.
XX
PN US2003044945-A1.
XX
PD 06-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142419.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-492275/46.
DR N-PSDB; ACD98660.
XX
PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
PT chromosome markers, or in generating probes.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention describes an isolated nucleic acid encoding a PRO (secreted
CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be
CC used to generate either transgenic animals or knock-out animals useful in
CC developing and screening of therapeutically useful reagents. The nucleic
CC acids may also be used in gene therapy, in chromosome identification, as
CC chromosome markers, or in generating probes. The PRO polypeptides are
CC useful as molecular markers for protein electrophoresis, and the isolated
CC nucleic acids may be used for recombinantly expressing those markers. The
CC PRO polypeptides and nucleic acids may also be used in tissue typing.
CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. This is the amino acid sequence of a novel human secreted and
CC transmembrane PRO polypeptide
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 56
ADA94593
ID ADA94593 standard; protein; 90 AA.
XX
AC ADA94593;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003059832-A1.

XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997349.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.

PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 57
ADA74600
ID ADA74600 standard; protein; 90 AA.
XX
AC ADA74600;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068798-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140928.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.

PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625490/59.
DR N-PSDB; ADA74599.
XX
PT Novel secreted and transmembrane PRO polypeptides and polynucleotides
PT encoding them, useful for treating bone disorders, arthritis, heart
PT attack, injuries, tumors, and stimulating release of Tumor Necrosis
PT Factor-alpha from human blood.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 58
ADB24833
ID ADB24833 standard; protein; 90 AA.
XX
AC ADB24833;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 474.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077713-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127839.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755068/71.
DR N-PSDB; ADB24832.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and

```
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 59
ADA82357
ID   ADA82357 standard; protein; 90 AA.
XX
AC   ADA82357;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082701-A1.
XX
PD   01-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128686.
XX
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   02-JUN-2000; 2000WO-US015264.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755110/71.
DR   N-PSDB; ADA82356.
XX
PT   PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT   tumor or for tissue typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
```

```
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 60
ADA75320
ID   ADA75320 standard; protein; 90 AA.
XX
AC   ADA75320;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003073216-A1.
XX
PD   17-APR-2003.
XX
PF   30-MAY-2002; 2002US-00160498.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000;   2000WO-US000219.
PR   06-JAN-2000;   2000WO-US000277.
PR   06-JAN-2000;   2000WO-US000376.
PR   11-FEB-2000;   2000WO-US003565.
PR   18-FEB-2000;   2000WO-US004341.
PR   18-FEB-2000;   2000WO-US004342.
PR   22-FEB-2000;   2000WO-US004414.
PR   24-FEB-2000;   2000WO-US004914.
PR   24-FEB-2000;   2000WO-US005004.
PR   01-MAR-2000;   2000WO-US005601.
PR   02-MAR-2000;   2000WO-US005746.
PR   02-MAR-2000;   2000WO-US005841.
PR   10-MAR-2000;   2000WO-US006319.
PR   15-MAR-2000;   2000WO-US006884.
PR   20-MAR-2000;   2000WO-US007377.
PR   21-MAR-2000;   2000WO-US007532.
PR   30-MAR-2000;   2000WO-US008439.
PR   17-MAY-2000;   2000WO-US013705.
PR   22-MAY-2000;   2000WO-US014042.
PR   30-MAY-2000;   2000WO-US014941.
PR   02-JUN-2000;   2000WO-US015264.
PR   28-JUL-2000;   2000WO-US020710.
PR   11-AUG-2000;   2000WO-US022031.
PR   23-AUG-2000;   2000WO-US023522.
PR   24-AUG-2000;   2000WO-US023328.
PR   08-NOV-2000;   2000WO-US030952.
PR   10-NOV-2000;   2000WO-US030873.
PR   01-DEC-2000;   2000WO-US032678.
PR   20-DEC-2000;   2000US-00747259.
PR   20-DEC-2000;   2000WO-US034956.
PR   28-FEB-2001;   2001US-00796498.
PR   28-FEB-2001;   2001WO-US006520.
PR   01-MAR-2001;   2001WO-US006666.
PR   09-MAR-2001;   2001US-00802706.
PR   14-MAR-2001;   2001US-00808689.
PR   22-MAR-2001;   2001US-00816744.
PR   05-APR-2001;   2001US-00828366.
PR   10-MAY-2001;   2001US-00854208.
PR   10-MAY-2001;   2001US-00854280.
PR   18-MAY-2001;   2001US-00860216.
PR   25-MAY-2001;   2001US-00866028.
PR   25-MAY-2001;   2001US-00866034.
PR   25-MAY-2001;   2001WO-US017092.
PR   01-JUN-2001;   2001US-00872035.
PR   01-JUN-2001;   2001WO-US017800.
PR   05-JUN-2001;   2001US-00874503.
PR   14-JUN-2001;   2001US-00882636.
PR   19-JUN-2001;   2001US-00886342.
PR   20-JUN-2001;   2001WO-US019692.
PR   21-JUN-2001;   2001US-00887879.
PR   22-JUN-2001;   2001WO-US020116.
PR   29-JUN-2001;   2001WO-US021066.
PR   09-JUL-2001;   2001WO-US021735.
PR   18-JUL-2001;   2001US-00908827.
PR   06-AUG-2001;   2001US-00924419.
PR   09-AUG-2001;   2001US-00927796.
PR   16-AUG-2001;   2001US-00931836.
PR   19-DEC-2001;   2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-765392/72.
DR   N-PSDB; ADA75319.
XX
PT   New secreted and transmembrane PRO polypeptides useful for stimulating
PT   the release of tumor necrosis factor alpha in human blood and detecting
PT   the presence of tumor in a mammal.
XX
PS   Claim 12; Fig 474; 638pp; English.
```

```
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 61
ADA85398
ID   ADA85398 standard; protein; 90 AA.
XX
AC   ADA85398;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082695-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127846.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786909/74.
DR   N-PSDB; ADA85397.
XX
PT   New nucleic acid encoding a PRO polypeptide, useful for preparing a
PT   composition for treating e.g. tumor by gene therapy, or for tissue
PT   typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 62
ADA84846
ID   ADA84846 standard; protein; 90 AA.
XX
AC   ADA84846;
```

XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082708-A1.
XX
PD 01-MAY-2003.
XX
PF 15-MAY-2002; 2002US-00146729.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786911/74.
DR N-PSDB; ADA84845.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 63
ADB30102
ID ADB30102 standard; protein; 90 AA.
XX
AC ADB30102;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073214-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124822.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.

```
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-720081/68.
DR   N-PSDB; ADB30101.
XX
PT   Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT   the release of tumor necrosis factor alpha and detecting the presence of
PT   a tumor in a mammal.
XX
PS   Claim 12; Fig 474; 638pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 64
ADA80630
ID   ADA80630 standard; protein; 90 AA.
XX
AC   ADA80630;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
```

KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082761-A1.
XX
PD 01-MAY-2003.
XX
PF 12-APR-2002; 2002US-00121061.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755115/71.
DR N-PSDB; ADA80629.
XX
PT New PRO polypeptides useful for treating diabetes, hyper- or hypo-
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,
PT various coagulation disorders and tumors.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 65
ADA75872
ID ADA75872 standard; protein; 90 AA.
XX
AC ADA75872;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082703-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128691.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zharg Z;
XX
DR WPI; 2003-765414/72.
DR N-PSDB; ADA75871.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 66
ADA38818
ID ADA38818 standard; protein; 90 AA.
XX
AC ADA38818;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW PRO; secreted protein; transmembrane protein; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer.
XX
OS Homo sapiens.
XX
PN US2003059780-A1.
XX

PD 27-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00991854.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.

PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 07-SEP-2000; 2000US-0230978P.
PR 08-NOV-2000; 2000WO-US030952.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 67
ADA47097
ID ADA47097 standard; protein; 90 AA.
XX
AC ADA47097;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003073210-A1.
XX
PD 17-APR-2003.
XX
PF 11-APR-2002; 2002US-00121045.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-644800/61.
DR N-PSDB; ADA47096.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 68
ADB25393
ID ADB25393 standard; protein; 90 AA.
XX
AC ADB25393;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 474.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077715-A1.
XX
PD 24-APR-2003.
XX
PF 23-APR-2002; 2002US-00128693.
XX
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 02-JUN-2000; 2000WO-US015264.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755070/71.
DR N-PSDB; ADB25392.

```
XX
PT   New isolated, secreted and transmembrane PRO nucleic acids, useful for
PT   the diagnosis, prevention and/or treatment of tumors, such as lung,
PT   colon, breast, prostate, rectal, cervical and/or liver tumors.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 69
ADA93569
ID   ADA93569 standard; protein; 90 AA.
XX
AC   ADA93569;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077721-A1.
XX
PD   24-APR-2003.
XX
PF   24-APR-2002; 2002US-00131837.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755076/71.
DR   N-PSDB; ADA93568.
XX
PT   New PRO nucleic acid, useful for recombinantly producing a PRO
PT   polypeptide and for manufacturing a medicament for diagnosing or treating
PT   tumor.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 70
ADB26919
ID   ADB26919 standard; protein; 90 AA.
XX
AC   ADB26919;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003092147-A1.
XX
PD   15-MAY-2003.
XX
PF   11-APR-2002; 2002US-00121051.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-777249/73.
DR   N-PSDB; ADB26918.
XX
PT   Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
```

PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 71
ADB31206
ID ADB31206 standard; protein; 90 AA.
XX
AC ADB31206;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003096386-A1.
XX
PD 22-MAY-2003.
XX
PF 11-APR-2002; 2002US-00121042.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.

PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786990/74.
DR N-PSDB; ADB31205.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 72
ADA92939
ID ADA92939 standard; protein; 90 AA.
XX
AC ADA92939;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003060407-A1.
XX
PD 27-MAR-2003.
XX
PF 14-NOV-2001; 2001US-00990440.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.

PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 73
ADA61134
ID ADA61134 standard; protein; 90 AA.
XX
AC ADA61134;
XX
DT 20-NOV-2003 (first entry)
XX
DE Homo sapiens.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Novel.
OS human.
OS secreted.
OS and.
OS transmembrane.
OS protein.
OS PRO1159.
XX
PN US2003049817-A1.
XX
PD 13-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00142423.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
PR 10-MAR-2009; 2000WO-US006319.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-695893/66.
DR N-PSDB; ADA61133.
XX
PT New secreted and transmembrane PRO polypeptide and nucleic acid, useful
PT for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 658pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 74
ADB24281

ID ADB24281 standard; protein; 90 AA.
XX
AC ADB24281;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 474.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077714-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127901.
XX
PR 17-JUN-1998; 98US-0089599P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-NOV-1999; 99WO-US028313.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755069/71.
DR N-PSDB; ADB24280.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

```
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 75
ADA96610
ID   ADA96610 standard; protein; 90 AA.
XX
AC   ADA96610;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082690-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127837.
XX
PR   01-SEP-1998;   98US-0098750P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755107/71.
DR   N-PSDB; ADA96609.
XX
PT   PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT   tumor or for tissue typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 76
ADA81182
ID   ADA81182 standard; protein; 90 AA.
XX
AC   ADA81182;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
```

```
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082702-A1.
XX
PD   01-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128690.
XX
PR   02-MAR-2000; 2000WO-US005841.
PR   30-MAY-2000; 2000WO-US014941.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-755111/71.
DR   N-PSDB; ADA81181.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 77
ADA96058
ID   ADA96058 standard; protein; 90 AA.
XX
AC   ADA96058;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082759-A1.
XX
PD   01-MAY-2003.
XX
PF   11-APR-2002; 2002US-00121040.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
```

PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755114/71.
DR N-PSDB; ADA96057.
XX
PT New isolated PRO polypeptides, useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders and tumors.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 78
ADB26367
ID ADB26367 standard; protein; 90 AA.
XX
AC ADB26367;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX

OS Homo sapiens.
XX
PN US2003082760-A1.
XX
PD 01-MAY-2003.
XX
PF 12-APR-2002; 2002US-00121056.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-777204/73.
DR N-PSDB; ADB26366.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

```
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 6;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 79
ADB21852
ID   ADB21852 standard; protein; 90 AA.
XX
AC   ADB21852;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082765-A1.
XX
PD   01-MAY-2003.
XX
PF   17-MAY-2002; 2002US-00147492.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
```

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786920/74.
DR N-PSDB; ADB21851.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 6; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 80
ADA77631
ID ADA77631 standard; protein; 90 AA.
XX
AC ADA77631;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068797-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140921.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.

PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-625489/59.
DR N-PSDB; ADA77630.
XX
PT Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801
PT and PRO1114, useful in the preparation of a medicament for treating a
PT condition responsive to PRO polypeptide, and as therapeutic agents e.g.
PT vaccines.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 81
ADB18371
ID ADB18371 standard; protein; 90 AA.
XX
AC ADB18371;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077710-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127825.
XX
PR 22-OCT-1998; 98US-0105169P.

PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755065/71.
DR N-PSDB; ADB18370.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
||||||||||||||||||||||||||||||
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 82
ADA87054

ID ADA87054 standard; protein; 90 AA.
XX
AC ADA87054;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082709-A1.
XX
PD 01-MAY-2003.
XX
PF 15-MAY-2002; 2002US-00146791.
XX
PR 17-AUG-1998; 98US-0096895P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786912/74.
DR N-PSDB; ADA87053.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,
PT for preparing a composition for treating e.g., tumor, or for tissue
PT typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural

CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 83
ADA88157
ID ADA88157 standard; protein; 90 AA.
XX
AC ADA88157;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082700-A1.
XX
PD 01-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128684.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786910/74.
DR N-PSDB; ADA88156.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 84
ADA46545
ID ADA46545 standard; protein; 90 AA.
XX
AC ADA46545;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003054516-A1.
XX
PD 20-MAR-2003.
XX
PF 12-APR-2002; 2002US-00121050.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-521853/49.
DR N-PSDB; ADA46544.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor.
XX
PS Claim 12; Fig 474; 200pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
||||||||||||||||||||||||||||||

```
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 85
ADB28575
ID   ADB28575 standard; protein; 90 AA.
XX
AC   ADB28575;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082699-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127851.
XX
PR   17-JUN-1998;   98US-0089599P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-NOV-1999;   99WO-US028313.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-777202/73.
DR   N-PSDB; ADB28574.
XX
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 86
ADB29127
ID   ADB29127 standard; protein; 90 AA.
XX
AC   ADB29127;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082706-A1.
XX
PD   01-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131836.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforgre L,  Desnoyers L,  Filvaroff E;
PI   Gao W,  Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-777203/73.
DR   N-PSDB; ADB29126.
XX
```

PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 87
ABO53223
ID ABO53223 standard; protein; 90 AA.
XX
AC ABO53223;
XX
DT 14-OCT-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW adrenal cortical capillary endothelial cell; angiogenesis; wound healing;
KW diabetes; obesity; hyper-insulinaemia; hypo-insulinaemia;
KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
KW sports injury; arthritis; kidney mesangial cell proliferation;
KW kidney disorder; Berger disease; neuropathy; coeliac disease;
KW dermatitis herpetiformis; Crohn's disease; tumour; cancer.
XX
OS Homo sapiens.
XX
PN US2003044806-A1.
XX
PD 06-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00998156.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.

PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 88
ADA77079
ID ADA77079 standard; protein; 90 AA.
XX
AC ADA77079;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.

XX
PN US2003059909-A1.
XX
PD 27-MAR-2003.
XX
PF 10-MAY-2002; 2002US-00143032.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-540684/51.
DR N-PSDB; ADA77078.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 474; 660pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating

```
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 89
ADA22500
ID   ADA22500 standard; protein; 90 AA.
XX
AC   ADA22500;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane polypeptide PRO1159.
XX
KW   human; tumour; cancer; colorectal cancer; gene therapy;
KW   chondrocyte differentiation; VEGF inhibition;
KW   vascular endothelial growth factor; Alzheimer's disease;
KW   Parkinson's disease; atherosclerosis; cystic fibrosis;
KW   multiple sclerosis; ovarian cancer; tissue typing.
XX
OS   Homo sapiens.
XX
PN   US2003040473-A1.
XX
PD   27-FEB-2003.
XX
PF   19-NOV-2001; 2001US-00989726.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
```

PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 90
ADA88709
ID ADA88709 standard; protein; 90 AA.
XX
AC ADA88709;
XX
DT 20-NOV-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003073213-A1.
XX
PD 17-APR-2003.
XX
PF 17-APR-2002; 2002US-00124819.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-743816/70.
DR N-PSDB; ADA88708.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, detecting the presence of tumor in a mammal, or
PT modulating the uptake of glucose or free fatty acid by skeletal muscle
PT cells or adipocyte cells.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 91
ADA97714
ID ADA97714 standard; protein; 90 AA.
XX
AC ADA97714;
XX
DT 20-NOV-2003 (first entry)
XX

DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082686-A1.
XX
PD 01-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125926.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755106/71.
DR N-PSDB; ADA97713.
XX
PT Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 666pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.

XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 92
ADB27471
ID ADB27471 standard; protein; 90 AA.
XX
AC ADB27471;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003022239-A1.
XX
PD 30-JAN-2003.
XX
PF 12-APR-2002; 2002US-00121049.
XX
PR 18-JUN-1997; 97US-0049911P.
PR 26-AUG-1997; 97US-0056974P.
PR 17-SEP-1997; 97US-0059113P.
PR 17-SEP-1997; 97US-0059115P.
PR 17-SEP-1997; 97US-0059117P.
PR 17-SEP-1997; 97US-0059122P.
PR 17-SEP-1997; 97US-0059184P.
PR 18-SEP-1997; 97US-0059263P.
PR 19-SEP-1997; 97US-0059352P.
PR 19-SEP-1997; 97US-0059588P.
PR 24-SEP-1997; 97US-0059836P.
PR 17-OCT-1997; 97US-0062250P.
PR 17-OCT-1997; 97US-0062285P.
PR 17-OCT-1997; 97US-0062287P.
PR 17-OCT-1997; 97US-0063755P.
PR 24-OCT-1997; 97US-0062814P.
PR 24-OCT-1997; 97US-0062816P.
PR 24-OCT-1997; 97US-0063045P.
PR 24-OCT-1997; 97US-0063082P.
PR 24-OCT-1997; 97US-0063127P.
PR 27-OCT-1997; 97US-0063327P.
PR 27-OCT-1997; 97US-0063329P.
PR 28-OCT-1997; 97US-0063550P.
PR 28-OCT-1997; 97US-0063561P.
PR 29-OCT-1997; 97US-0063704P.
PR 29-OCT-1997; 97US-0063733P.
PR 29-OCT-1997; 97US-0063735P.
PR 29-OCT-1997; 97US-0063738P.

PR 03-NOV-1997; 97US-0064248P.
PR 07-NOV-1997; 97US-0064809P.
PR 12-NOV-1997; 97US-0065186P.
PR 17-NOV-1997; 97US-0065846P.
PR 21-NOV-1997; 97US-0066364P.
PR 24-NOV-1997; 97US-0066453P.
PR 24-NOV-1997; 97US-0066511P.
PR 24-NOV-1997; 97US-0066770P.
PR 11-DEC-1997; 97US-0069212P.
PR 11-DEC-1997; 97US-0069278P.
PR 11-DEC-1997; 97US-0069334P.
PR 16-DEC-1997; 97US-0069694P.
PR 23-JAN-1998; 98US-0072320P.
PR 04-FEB-1998; 98US-0073612P.
PR 09-FEB-1998; 98US-0074086P.
PR 09-FEB-1998; 98US-0074092P.
PR 12-MAR-1998; 98US-0077791P.
PR 20-MAR-1998; 98US-0078910P.
PR 25-MAR-1998; 98US-0079294P.
PR 27-MAR-1998; 98US-0079663P.
PR 27-MAR-1998; 98US-0079728P.
PR 31-MAR-1998; 98US-0080165P.
PR 09-APR-1998; 98US-0081229P.
PR 14-APR-1998; 98US-0081695P.
PR 15-APR-1998; 98US-0081817P.
PR 15-APR-1998; 98US-0081818P.
PR 24-APR-1998; 98US-0082999P.
PR 28-APR-1998; 98US-0083322P.
PR 29-APR-1998; 98US-0083545P.
PR 07-MAY-1998; 98US-0084600P.
PR 07-MAY-1998; 98US-0084627P.
PR 07-MAY-1998; 98US-0084637P.
PR 12-MAY-1998; 98US-0085149P.
PR 13-MAY-1998; 98US-0085323P.
PR 13-MAY-1998; 98US-0085338P.
PR 13-MAY-1998; 98US-0085339P.
PR 15-MAY-1998; 98US-0085579P.
PR 15-MAY-1998; 98US-0085697P.
PR 15-MAY-1998; 98US-0085704P.
PR 22-MAY-1998; 98US-0086414P.
PR 22-MAY-1998; 98US-0086430P.
PR 28-MAY-1998; 98US-0087106P.
PR 04-JUN-1998; 98US-0088026P.
PR 10-JUN-1998; 98US-0088730P.
PR 10-JUN-1998; 98US-0088741P.
PR 10-JUN-1998; 98US-0088810P.
PR 11-JUN-1998; 98US-0088858P.
PR 12-JUN-1998; 98WO-US012456.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089599P.
PR 18-JUN-1998; 98US-0089907P.
PR 19-JUN-1998; 98US-0089947P.
PR 23-JUN-1998; 98US-0090349P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090538P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUL-1998; 98US-0091519P.
PR 07-JUL-1998; 98US-0091982P.
PR 14-JUL-1998; 98WO-US014552.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095325P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096895P.
PR 18-AUG-1998; 98US-0096960P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.

```
  Query Match           100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 93
ADB22404
ID   ADB22404 standard; protein; 90 AA.
XX
AC   ADB22404;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087344-A1.
XX
PD   08-MAY-2003.
XX
PF   16-APR-2002; 2002US-00123905.
XX
PR   18-JUN-1997;   97US-0049911P.
PR   26-AUG-1997;   97US-0056974P.
PR   17-SEP-1997;   97US-0059113P.
PR   17-SEP-1997;   97US-0059115P.
PR   17-SEP-1997;   97US-0059117P.
PR   17-SEP-1997;   97US-0059122P.
PR   17-SEP-1997;   97US-0059184P.
PR   18-SEP-1997;   97US-0059263P.
PR   19-SEP-1997;   97US-0059352P.
PR   19-SEP-1997;   97US-0059588P.
PR   24-SEP-1997;   97US-0059836P.
PR   17-OCT-1997;   97US-0062250P.
PR   17-OCT-1997;   97US-0062285P.
PR   17-OCT-1997;   97US-0062287P.
PR   17-OCT-1997;   97US-0063755P.
PR   24-OCT-1997;   97US-0062814P.
PR   24-OCT-1997;   97US-0062816P.
PR   24-OCT-1997;   97US-0063045P.
PR   24-OCT-1997;   97US-0063082P.
PR   24-OCT-1997;   97US-0063127P.
PR   27-OCT-1997;   97US-0063327P.
PR   27-OCT-1997;   97US-0063329P.
PR   28-OCT-1997;   97US-0063550P.
PR   28-OCT-1997;   97US-0063561P.
PR   29-OCT-1997;   97US-0063704P.
PR   29-OCT-1997;   97US-0063733P.
PR   29-OCT-1997;   97US-0063735P.
PR   29-OCT-1997;   97US-0063738P.
PR   03-NOV-1997;   97US-0064248P.
PR   07-NOV-1997;   97US-0064809P.
PR   12-NOV-1997;   97US-0065186P.
PR   17-NOV-1997;   97US-0065846P.
PR   21-NOV-1997;   97US-0066364P.
PR   24-NOV-1997;   97US-0066453P.
PR   24-NOV-1997;   97US-0066511P.
PR   24-NOV-1997;   97US-0066770P.
PR   11-DEC-1997;   97US-0069212P.
PR   11-DEC-1997;   97US-0069278P.
PR   11-DEC-1997;   97US-0069334P.
PR   16-DEC-1997;   97US-0069694P.
PR   23-JAN-1998;   98US-0072320P.
PR   04-FEB-1998;   98US-0073612P.
PR   09-FEB-1998;   98US-0074086P.
PR   09-FEB-1998;   98US-0074092P.
PR   12-MAR-1998;   98US-0077791P.
PR   20-MAR-1998;   98US-0078910P.
PR   25-MAR-1998;   98US-0079294P.
PR   27-MAR-1998;   98US-0079663P.
PR   27-MAR-1998;   98US-0079728P.
PR   31-MAR-1998;   98US-0080165P.
PR   09-APR-1998;   98US-0081229P.
PR   14-APR-1998;   98US-0081695P.
PR   15-APR-1998;   98US-0081817P.
PR   15-APR-1998;   98US-0081818P.
PR   24-APR-1998;   98US-0082999P.
PR   28-APR-1998;   98US-0083322P.
PR   29-APR-1998;   98US-0083545P.
PR   07-MAY-1998;   98US-0084600P.
PR   07-MAY-1998;   98US-0084627P.
PR   07-MAY-1998;   98US-0084637P.
PR   12-MAY-1998;   98US-0085149P.
PR   13-MAY-1998;   98US-0085323P.
PR   13-MAY-1998;   98US-0085338P.
PR   13-MAY-1998;   98US-0085339P.
PR   15-MAY-1998;   98US-0085579P.
PR   15-MAY-1998;   98US-0085697P.
PR   15-MAY-1998;   98US-0085704P.
PR   22-MAY-1998;   98US-0086414P.
PR   22-MAY-1998;   98US-0086430P.
PR   28-MAY-1998;   98US-0087106P.
PR   04-JUN-1998;   98US-0088026P.
PR   10-JUN-1998;   98US-0088730P.
PR   10-JUN-1998;   98US-0088741P.
PR   10-JUN-1998;   98US-0088810P.
PR   11-JUN-1998;   98US-0088858P.
PR   12-JUN-1998;   98WO-US012456.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089599P.
PR   18-JUN-1998;   98US-0089907P.
PR   19-JUN-1998;   98US-0089947P.
PR   23-JUN-1998;   98US-0090349P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090538P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   02-JUL-1998;   98US-0091519P.
PR   07-JUL-1998;   98US-0091982P.
PR   14-JUL-1998;   98WO-US014552.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095325P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096895P.
PR   18-AUG-1998;   98US-0096960P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
```

PR 26-AUG-1998; 98US-0097951P.
PR 26-AUG-1998; 98US-0097986P.
PR 28-AUG-1998; 98WO-US017888.
PR 31-AUG-1998; 98US-0098525P.
PR 01-SEP-1998; 98US-0098750P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099601P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099803P.
PR 10-SEP-1998; 98US-0099816P.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98US-0100262P.
PR 14-SEP-1998; 98US-0100263P.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101741P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98WO-US021141.
PR 13-OCT-1998; 98US-0104080P.
PR 20-OCT-1998; 98US-0104987P.
PR 22-OCT-1998; 98US-0105169P.
PR 28-OCT-1998; 98US-0106030P.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108925P.
PR 20-NOV-1998; 98US-0109304P.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 15-DEC-1998; 98US-0112743P.
PR 16-DEC-1998; 98US-0112850P.
PR 22-DEC-1998; 98US-0113296P.
PR 22-DEC-1998; 98US-0113299P.
PR 22-DEC-1998; 98US-0113300P.
PR 22-DEC-1998; 98US-0113313P.
PR 22-DEC-1998; 98US-0113314P.
PR 22-DEC-1998; 98US-0113315P.
PR 22-DEC-1998; 98US-0113510P.
PR 22-DEC-1998; 98US-0113511P.
PR 23-DEC-1998; 98US-0113605P.
PR 23-DEC-1998; 98US-0113621P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-JAN-1999; 99US-0115549P.
PR 12-JAN-1999; 99US-0115557P.
PR 12-JAN-1999; 99US-0115560P.
PR 12-JAN-1999; 99US-0115562P.
PR 12-JAN-1999; 99US-0115564P.
PR 12-JAN-1999; 99US-0115630P.
PR 12-JAN-1999; 99US-0115705P.
PR 12-JAN-1999; 99US-0115733P.
PR 20-JAN-1999; 99US-0116533P.
PR 01-FEB-1999; 99US-0118210P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 94
ABO22593
ID ABO22593 standard; protein; 90 AA.
XX
AC ABO22593;
XX
DT 04-SEP-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW Human; PRO; secreted protein; transmembrane protein; antidiabetic;
KW cytostatic; antirheumatic; antiarthritic; antiulcer; neuroprotective;
KW antiinflammatory; antibacterial; immunosuppressive; gene therapy;
KW diabetes; cancer; rheumatoid arthritis; ulcers;
KW amyotrophic lateral sclerosis; inflammatory condition; septic shock.
XX
OS Homo sapiens.
XX
PN US2003017982-A1.
XX
PD 23-JAN-2003.
XX
PF 16-NOV-2001; 2001US-00990441.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.

PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 13-AUG-1998; 98US-0096413P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

```
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 95
ADA06666
ID   ADA06666 standard; protein; 90 AA.
XX
AC   ADA06666;
XX
DT   29-JAN-2004  (revised)
DT   06-NOV-2003  (first entry)
XX
DE   Human secreted/transmembrane PRO polypeptide #118.
XX
KW   human; tissue typing; cardiac insufficiency disorder; angiogenesis;
KW   wound healing; tumour; immune response; retinal disorder; retinal injury;
KW   sight loss; age-related macular degeneration; AMD; kidney disorder;
KW   mesangial cell function; Berger disease; nephropathy; dermatitis;
KW   herpetiform; Crohn's disease; sports injury; arthritis.
XX
OS   Homo sapiens.
XX
PN   US2003049638-A1.
XX
PD   13-MAR-2003.
XX
PF   16-NOV-2001; 2001US-00991157.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   13-AUG-1998;   98US-0096413P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
```

PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 96
ADA39359
ID ADA39359 standard; protein; 90 AA.
XX
AC ADA39359;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003059782-A1.
XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997628.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.

PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

```
RESULT 97
ADA67095
ID   ADA67095 standard; protein; 90 AA.
XX
AC   ADA67095;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003068793-A1.
XX
PD   10-APR-2003.
XX
PF   15-APR-2002; 2002US-00123108.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-695925/66.
DR   N-PSDB; ADA67094.
XX
PT   Novel secreted and transmembrane PRO polypeptides useful for stimulating
PT   release of tumor necrosis factor-alpha from human blood and detecting the
PT   presence of a tumor in a mammal.
XX
PS   Claim 12; Fig 474; 660pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
```

CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 98
ADB22956
ID ADB22956 standard; protein; 90 AA.
XX
AC ADB22956;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077711-A1.
XX
PD 24-APR-2003.
XX
PF 22-APR-2002; 2002US-00127829.
XX
PR 22-OCT-1998; 98US-0105169P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755066/71.
DR N-PSDB; ADB22955.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, as diagnostic markers for the presence of a disease
PT condition, or as therapeutic targets for treating tumors, diabetes,
PT obesity or arthritis.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

```
                    ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 99
ADB23729
ID   ADB23729 standard; protein; 90 AA.
XX
AC   ADB23729;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide SEQ ID NO 474.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077712-A1.
XX
PD   24-APR-2003.
XX
PF   22-APR-2002; 2002US-00127835.
XX
PR   20-OCT-1998;   98US-0104987P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755067/71.
DR   N-PSDB; ADB23728.
XX
PT   New isolated, secreted and transmembrane PRO nucleic acid, useful for the
PT   diagnosis, prevention and/or treatment of tumors, such as lung, colon,
PT   breast, prostate, rectal, cervical and/or liver tumors.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 100
ADA92451
ID   ADA92451 standard; protein; 90 AA.
XX
AC   ADA92451;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082712-A1.
XX
PD   01-MAY-2003.
XX
PF   16-MAY-2002; 2002US-00147512.
XX
PR   15-MAY-1998;   98US-0085697P.
PR   08-MAR-1999;   99WO-US005028.
PR   25-AUG-1999;   99US-00380138.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786915/74.
DR   N-PSDB; ADA92450.
XX
```

```
PT   New PRO nucleic acid, useful for preparing a composition for treating
PT   e.g., tumor or for tissue typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 101
ADB15514
ID   ADB15514 standard; protein; 90 AA.
XX
AC   ADB15514;
XX
DT   20-NOV-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003087352-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127824.
XX
PR   17-AUG-1998;   98US-0096891P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   30-MAY-2000; 2000WO-US014941.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-786943/74.
DR   N-PSDB; ADB15513.
XX
PT   New PRO nucleic acid, useful for producing a recombiannt PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

```
                     ||||||||||||||||||||||||||||||
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 102
ADB38766
ID   ADB38766 standard; protein; 90 AA.
XX
AC   ADB38766;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082766-A1.
XX
PD   01-MAY-2003.
XX
PF   30-MAY-2002; 2002US-00158782.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786921/74.
DR   N-PSDB; ADB38765.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT   in gene therapy, detecting the presence of tumor in a mammal, or
PT   modulating the uptake of glucose or free fatty acid by skeletal muscle
PT   cells or adipocyte cells.
XX
PS   Claim 12; Fig 474; 660pp; English.
```

XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 103
ADB96385
ID ADB96385 standard; protein; 90 AA.
XX
AC ADB96385;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003054403-A1.
XX
PD 20-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997559.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.

PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 104
ADB38214
ID ADB38214 standard; protein; 90 AA.
XX
AC ADB38214;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087347-A1.
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125921.
XX
PR 17-AUG-1998; 98US-0096791P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.

PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786938/74.
DR N-PSDB; ADB38213.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 105
ADB66686
ID ADB66686 standard; protein; 90 AA.
XX
AC ADB66686;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082689-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127831.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.

PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786905/74.
DR N-PSDB; ADB66685.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g. tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 106
ADB89766
ID ADB89766 standard; protein; 90 AA.
XX
AC ADB89766;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082698-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127850.
XX
PR 20-AUG-1998; 98US-0097218P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-743896/70.
DR N-PSDB; ADB89765.
XX
PT New PRO nucleic acids and encoded polypeptides, useful in the treatment
PT of cancer.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 107
ADB90498
ID ADB90498 standard; protein; 90 AA.
XX
AC ADB90498;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003082762-A1.
XX
PD 01-MAY-2003.
XX
PF 15-APR-2002; 2002US-00123235.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.

```
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-743899/70.
DR   N-PSDB; ADB90497.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT   in gene therapy, and in the detection and treatment of tumor in a mammal.
XX
PS   Claim 12; Fig 474; 649pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 108
ADB39599
ID   ADB39599 standard; protein; 90 AA.
XX
AC   ADB39599;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082764-A1.
XX
PD   01-MAY-2003.
XX
PF   03-MAY-2002; 2002US-00137868.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
```

PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786919/74.
DR N-PSDB; ADB39598.
XX
PT New secreted and transmembrane PRO polypeptide useful for detecting the
PT presence of tumor in a mammal, or modulating the uptake of glucose or
PT free fatty acid by skeletal muscle cells or adipocyte cells.
XX
PS Claim 12; Fig 474; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
||||||||||||||||||||||||||||||
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 109
ADB47222

```
ID   ADB47222 standard; protein; 90 AA.
XX
AC   ADB47222;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082687-A1.
XX
PD   01-MAY-2003.
XX
PF   19-APR-2002; 2002US-00125930.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-786904/74.
DR   N-PSDB; ADB47221.
XX
PT   New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 12; Fig 474; 627pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 110
ADB86829
ID   ADB86829 standard; protein; 90 AA.
XX
AC   ADB86829;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003082697-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127849.
XX
PR   20-OCT-1998;   98US-0104987P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-743895/70.
DR   N-PSDB; ADB86828.
XX
PT   New secreted and transmembrane PRO polypeptides, useful in the diagnosis
PT   and treatment of cancer.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
```

```
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 111
ADB77434
ID   ADB77434 standard; protein; 90 AA.
XX
AC   ADB77434;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inihibitor; cytokine release stimulator; tumour;
KW   lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003082696-A1.
XX
PD   01-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127848.
XX
PR   03-NOV-1998;   98US-0106934P.
PR   26-JUL-1999;   99US-0145698P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   05-JAN-2000; 2000WO-US000219.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755109/71.
DR   N-PSDB; ADB77433.
XX
PT   PRO nucleic acid, useful for preparing a composition for treating e.g.,
PT   tumor or for tissue typing.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 112
ADB34591
ID   ADB34591 standard; protein; 90 AA.
XX
AC   ADB34591;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide SEQ ID NO 474.
```

```
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077717-A1.
XX
PD   24-APR-2003.
XX
PF   24-APR-2002; 2002US-00131818.
XX
PR   07-OCT-1998;   98US-0103328P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   30-NOV-1999;   99WO-US028313.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-755072/71.
DR   N-PSDB; ADB34590.
XX
PT   New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT   acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT   such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT   tumors.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 113
ADB35695
ID   ADB35695 standard; protein; 90 AA.
XX
AC   ADB35695;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide SEQ ID NO 474.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077719-A1.
XX
PD   24-APR-2003.
XX
PF   24-APR-2002; 2002US-00131824.
XX
PR   09-FEB-1999;   99US-0119341P.
PR   01-DEC-1999;   99WO-US028634.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-755074/71.
DR   N-PSDB; ADB35694.
XX
PT   New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT   acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT   such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT   tumors.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
```

CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 114
ADB34039
ID ADB34039 standard; protein; 90 AA.
XX
AC ADB34039;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 474.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077716-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131813.
XX
PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755071/71.
DR N-PSDB; ADB34038.
XX
PT New secreted and transmembrane PRO polypeptides and nucleic acids, useful
PT in gene therapy, in chromosome and gene mapping, as chromosome markers,
PT in tissue typing, and in identifying chromosomes.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

```
RESULT 115
ADB35143
ID   ADB35143 standard; protein; 90 AA.
XX
AC   ADB35143;
XX
DT   04-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide SEQ ID NO 474.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003077718-A1.
XX
PD   24-APR-2003.
XX
PF   24-APR-2002; 2002US-00131823.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-755073/71.
DR   N-PSDB; ADB35142.
XX
PT   New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT   acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT   such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT   tumors.
XX
PS   Claim 12; Fig 474; 638pp; English.
XX
```

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 116
ADB36247
ID ADB36247 standard; protein; 90 AA.
XX
AC ADB36247;
XX
DT 04-DEC-2003 (first entry)
XX
DE Human PRO polypeptide SEQ ID NO 474.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003077720-A1.
XX
PD 24-APR-2003.
XX
PF 24-APR-2002; 2002US-00131830.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-755075/71.
DR N-PSDB; ADB36246.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 117
ADB46642
ID ADB46642 standard; protein; 90 AA.
XX
AC ADB46642;
XX
DT 04-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inihibitor; cytokine release stimulator; tumour;
KW lung tumoue; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003082692-A1.
XX
PD 01-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127842.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786906/74.
DR N-PSDB; ADB46641.
XX
PT New PRO nucleic acid, useful for preparing a composition for treating
PT e.g., tumor or for tissue typing.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 118
ADC57857
ID ADC57857 standard; protein; 90 AA.
XX
AC ADC57857;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003027754-A1.
XX
PD 06-FEB-2003.
XX
PF 14-NOV-2001; 2001US-00990438.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.

PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

```
PR   23-AUG-2000; 2000WO-US023522.

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 119
ADC55221
ID   ADC55221 standard; protein; 90 AA.
XX
AC   ADC55221;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide #118.
XX
KW   Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW   cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS   Homo sapiens.
XX
PN   US2003045463-A1.
XX
PD   06-MAR-2003.
XX
PF   16-NOV-2001; 2001US-00990437.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   13-AUG-1998;   98US-0096413P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
```

PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
||||||||||||||||||||||||||||||
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 120
ADC12088
ID ADC12088 standard; protein; 90 AA.
XX
AC ADC12088;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human secreted/transmembrane protein PRO1159.
XX
KW PRO; secreted protein; transmembrane protein;
KW hypertrophy of neonatal heart; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW c-fos induction; adipocyte cell; chondrocyte differentiation;
KW pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW cancer; human; colon cancer; lung cancer; breast cancer;
KW rod photoreceptor cell.
XX
OS Homo sapiens.
XX
PN US2003049681-A1.
XX
PD 13-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997514.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.

PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 121
ADC56510
ID   ADC56510 standard; protein; 90 AA.
XX
AC   ADC56510;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human PRO polypeptide #118.
XX
KW   Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW   cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS   Homo sapiens.
XX
PN   US2003064375-A1.
XX
PD   03-APR-2003.
XX
PF   15-NOV-2001; 2001US-00997857.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
```

```
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.

  Query Match           100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 122
ADC07565
ID   ADC07565 standard; protein; 90 AA.
XX
AC   ADC07565;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1159.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   c-fos induction; adipocyte cell; chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer;
KW   rod photoreceptor cell.
XX
OS   Homo sapiens.
XX
PN   US2003068647-A1.
XX
PD   10-APR-2003.
XX
PF   15-NOV-2001; 2001US-00997542.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
```

PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
||||||||||||||||||||||||||||||

```
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 123
ADC11555
ID   ADC11555 standard; protein; 90 AA.
XX
AC   ADC11555;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Human secreted/transmembrane protein PRO1159.
XX
KW   PRO; secreted protein; transmembrane protein;
KW   hypertrophy of neonatal heart; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   c-fos induction; adipocyte cell; chondrocyte differentiation;
KW   pancreatic beta-cell precursor differentiation; gene therapy; tumour;
KW   cancer; human; colon cancer; lung cancer; breast cancer;
KW   rod photoreceptor cell.
XX
OS   Homo sapiens.
XX
PN   US2003069403-A1.
XX
PD   10-APR-2003.
XX
PF   14-NOV-2001; 2001US-00993748.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
PR   07-JUL-1998;   98US-0091982P.
PR   09-JUL-1998;   98US-0092182P.
PR   10-JUL-1998;   98US-0092472P.
PR   20-JUL-1998;   98US-0093339P.
PR   30-JUL-1998;   98US-0094651P.
PR   04-AUG-1998;   98US-0095282P.
PR   04-AUG-1998;   98US-0095285P.
PR   04-AUG-1998;   98US-0095301P.
PR   04-AUG-1998;   98US-0095302P.
PR   04-AUG-1998;   98US-0095318P.
PR   04-AUG-1998;   98US-0095321P.
PR   04-AUG-1998;   98US-0095325P.
PR   10-AUG-1998;   98US-0095916P.
PR   10-AUG-1998;   98US-0095929P.
PR   10-AUG-1998;   98US-0096012P.
PR   11-AUG-1998;   98US-0096143P.
PR   11-AUG-1998;   98US-0096146P.
PR   12-AUG-1998;   98US-0096329P.
PR   17-AUG-1998;   98US-0096757P.
PR   17-AUG-1998;   98US-0096766P.
PR   17-AUG-1998;   98US-0096768P.
PR   17-AUG-1998;   98US-0096773P.
PR   17-AUG-1998;   98US-0096791P.
PR   17-AUG-1998;   98US-0096867P.
PR   17-AUG-1998;   98US-0096891P.
PR   17-AUG-1998;   98US-0096894P.
PR   17-AUG-1998;   98US-0096895P.
PR   17-AUG-1998;   98US-0096897P.
PR   18-AUG-1998;   98US-0096949P.
PR   18-AUG-1998;   98US-0096950P.
```

```
PR   18-AUG-1998;   98US-0096959P.
PR   18-AUG-1998;   98US-0096960P.
PR   18-AUG-1998;   98US-0097022P.
PR   19-AUG-1998;   98US-0097141P.
PR   20-AUG-1998;   98US-0097218P.
PR   24-AUG-1998;   98US-0097661P.
PR   26-AUG-1998;   98US-0097952P.
PR   26-AUG-1998;   98US-0097954P.
PR   26-AUG-1998;   98US-0097955P.
PR   26-AUG-1998;   98US-0097971P.
PR   26-AUG-1998;   98US-0097974P.
PR   26-AUG-1998;   98US-0097978P.
PR   26-AUG-1998;   98US-0097979P.
PR   26-AUG-1998;   98US-0097986P.
PR   26-AUG-1998;   98US-0098014P.
PR   31-AUG-1998;   98US-0098525P.
PR   16-SEP-1998;   98US-0100634P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.

  Query Match           100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

```
RESULT 124
ADC50515
ID   ADC50515 standard; protein; 90 AA.
XX
AC   ADC50515;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003092106-A1.
XX
PD   15-MAY-2003.
XX
PF   24-APR-2002; 2002US-00131822.
XX
PR   19-AUG-1998;   98US-0097141P.
PR   02-JUN-1999;   99WO-US012252.
PR   25-AUG-1999;   99US-00380137.
PR   30-MAR-2000; 2000WO-US008439.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801171/75.
DR   N-PSDB; ADC50514.
XX
PT   New secreted and transmembrane nucleic acid useful for treating
PT   inflammation, organ failure, atherosclerosis, cardiac injury,
PT   infertility, birth defects, premature aging, acquired immunodeficiency
PT   syndrome or cancer.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
```

CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 125
ADC72062
ID ADC72062 standard; protein; 90 AA.
XX
AC ADC72062;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092107-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131828.
XX
PR 07-OCT-1998; 98US-0103315P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801172/75.
DR N-PSDB; ADC72061.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 126
ADC60041
ID ADC60041 standard; protein; 90 AA.
XX
AC ADC60041;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;

KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092105-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131821.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801170/75.
DR N-PSDB; ADC60040.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX

SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 127
ADC53048
ID ADC53048 standard; protein; 90 AA.
XX
AC ADC53048;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein Seq ID474.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
PN US2003087365-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128689.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godwoski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801150/75.
DR N-PSDB; ADC53047.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 1; SEQ ID NO 474; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 128
ADC57402
ID ADC57402 standard; protein; 90 AA.
XX
AC ADC57402;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein Seq ID474.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
PN US2003087366-A1.
XX
PD 08-MAY-2003.
XX
PF 23-APR-2002; 2002US-00128694.
XX
PR 02-MAR-2000; 2000WO-US005841.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX

PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801151/75.
DR N-PSDB; ADC57401.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 1; SEQ ID NO 474; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 129
ADC60593
ID ADC60593 standard; protein; 90 AA.
XX
AC ADC60593;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087367-A1.
XX
PD 08-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131825.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.

PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801152/75.
DR N-PSDB; ADC60592.
XX
PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 130
ADC51068
ID ADC51068 standard; protein; 90 AA.
XX
AC ADC51068;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087361-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127841.
XX
PR 09-SEP-1998; 98US-0099536P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801146/75.
DR N-PSDB; ADC51067.
XX

PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 131
ADC65595
ID ADC65595 standard; protein; 90 AA.
XX
AC ADC65595;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003087362-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127844.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801147/75.
DR N-PSDB; ADC65594.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

```
                    ||||||||||||||||||||||||||||||
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 132
ADC54693
ID   ADC54693 standard; protein; 90 AA.
XX
AC   ADC54693;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID474.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087363-A1.
XX
PD   08-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128687.
XX
PR   10-SEP-1998;   98US-0099816P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801148/75.
DR   N-PSDB; ADC54692.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 1; SEQ ID NO 474; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is the amino acid sequence of a human PRO protein of the
CC   invention.
XX
SQ   Sequence 90 AA;

  Query Match           100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 133
ADC53654
ID   ADC53654 standard; protein; 90 AA.
XX
AC   ADC53654;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID474.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087364-A1.
XX
PD   08-MAY-2003.
XX
PF   23-APR-2002; 2002US-00128688.
XX
PR   09-FEB-1999;   99US-0119341P.
PR   01-DEC-1999;   99WO-US028634.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801149/75.
DR   N-PSDB; ADC53653.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
XX
PS   Claim 1; SEQ ID NO 474; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
```

```
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is the amino acid sequence of a human PRO protein of the
CC   invention.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 134
ADC59177
ID   ADC59177 standard; protein; 90 AA.
XX
AC   ADC59177;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID474.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087359-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127834.
XX
PR   17-SEP-1998;   98US-0100710P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801144/75.
DR   N-PSDB; ADC59176.
XX
PT   New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
PT   and for manufacturing a medicament for diagnosing or treating tumor.
XX
PS   Claim 1; SEQ ID NO 474; 637pp; English.
XX
CC   This invention relates to novel nucleic acids encoding human PRO secreted
CC   and transmembrane proteins. Extracellular proteins play important roles
CC   in the formation, differentiation and maintenance of multicellular
CC   organisms. The fate of many individual cells (for example proliferation,
CC   migration or differentiation) is typically governed by information
CC   received from other cells and the immediate environment. The information
CC   is often transmitted by secreted polypeptides (for example mitogenic
CC   factors, survival factors, cytotoxic factors, differentiation factors,
CC   neuropeptides and hormones) which are received and interpreted by diverse
CC   cell receptors or membrane bound proteins. These membrane bound proteins
CC   and receptors may be of use as pharmaceutical and diagnostic agents, such
CC   as in the blocking of receptor-ligand interactions. The current invention
CC   provides the amino acid sequences of novel human membrane bound receptors
CC   and proteins, along with the cDNA sequences encoding them. The novel
CC   proteins of the invention may have cytostatic activities through the
CC   stimulation of chondrocytes. The nucleic acids of the invention may be
CC   useful for the manufacture of a medicament for diagnosing or treating a
CC   tumour in a mammal. In addition, they may be useful for measuring or
CC   detecting the expression of a tumour associated gene. The present
CC   sequence is the amino acid sequence of a human PRO protein of the
CC   invention.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 135
ADC56055
ID   ADC56055 standard; protein; 90 AA.
XX
AC   ADC56055;
XX
DT   18-DEC-2003  (first entry)
XX
DE   Novel human secreted and transmembrane protein Seq ID474.
XX
KW   human; PRO; membrane bound protein; membrane bound receptor;
KW   cell proliferation; cell migration; cell differentiation;
KW   mitogenic factor; survival factor; cytotoxic factor;
KW   differentiation factor; neuropeptide; hormone; cell receptor;
KW   receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS   Homo sapiens.
XX
PN   US2003087360-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127836.
XX
PR   17-NOV-1998;   98US-0108802P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-AUG-2000; 2000WO-US023522.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801145/75.
DR   N-PSDB; ADC56054.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
```

XX
PS Claim 1; SEQ ID NO 474; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 136
ADC58625
ID ADC58625 standard; protein; 90 AA.
XX
AC ADC58625;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein Seq ID474.
XX
KW human; PRO; membrane bound protein; membrane bound receptor;
KW cell proliferation; cell migration; cell differentiation;
KW mitogenic factor; survival factor; cytotoxic factor;
KW differentiation factor; neuropeptide; hormone; cell receptor;
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour.
XX
OS Homo sapiens.
XX
PN US2003087346-A1.
XX
PD 08-MAY-2003.
XX
PF 17-APR-2002; 2002US-00124815.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801137/75.
DR N-PSDB; ADC58624.
XX
PT Isolated nucleic acid for use in industrial applications has at least 80
PT percent nucleic acid sequence identity to nucleotide sequence that
PT encodes amino acid sequence selected from amino acid sequence group.
XX
PS Claim 1; SEQ ID NO 474; 637pp; English.
XX
CC This invention relates to novel nucleic acids encoding human PRO secreted
CC and transmembrane proteins. Extracellular proteins play important roles
CC in the formation, differentiation and maintenance of multicellular
CC organisms. The fate of many individual cells (for example proliferation,
CC migration or differentiation) is typically governed by information
CC received from other cells and the immediate environment. The information
CC is often transmitted by secreted polypeptides (for example mitogenic
CC factors, survival factors, cytotoxic factors, differentiation factors,
CC neuropeptides and hormones) which are received and interpreted by diverse
CC cell receptors or membrane bound proteins. These membrane bound proteins
CC and receptors may be of use as pharmaceutical and diagnostic agents, such
CC as in the blocking of receptor-ligand interactions. The current invention
CC provides the amino acid sequences of novel human membrane bound receptors
CC and proteins, along with the cDNA sequences encoding them. The novel
CC proteins of the invention may have cytostatic activities through the
CC stimulation of chondrocytes. The nucleic acids of the invention may be
CC useful for the manufacture of a medicament for diagnosing or treating a
CC tumour in a mammal. In addition, they may be useful for measuring or
CC detecting the expression of a tumour associated gene. The present
CC sequence is the amino acid sequence of a human PRO protein of the
CC invention.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 137
ADC14677
ID ADC14677 standard; protein; 90 AA.
XX
AC ADC14677;
XX
DT 18-DEC-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003082546-A1.
XX
PD 01-MAY-2003.
XX
PF 28-AUG-2001; 2001US-00941992.
XX
PR 06-NOV-1996; 96US-00743698.
PR 16-JUN-1997; 97US-0049787P.
PR 16-JUN-1997; 97US-00876698.

PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97US-00965056.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-00105413.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98US-00168978.
PR 07-OCT-1998; 98WO-US021141.
PR 06-NOV-1998; 98US-00187368.
PR 01-DEC-1998; 98WO-US025108.
PR 07-DEC-1998; 98US-00202054.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.

PR 03-MAR-1999; 99US-00254311.
PR 08-MAR-1999; 99WO-US005028.
PR 09-MAR-1999; 99US-00254460.
PR 12-MAR-1999; 99US-00267213.
PR 12-MAR-1999; 99US-0123957P.
PR 12-APR-1999; 99US-00284291.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 25-AUG-1999; 99US-00380137.
PR 25-AUG-1999; 99US-00380138.
PR 25-AUG-1999; 99US-00380139.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 18-OCT-1999; 99US-00403296.
PR 12-NOV-1999; 99US-00423844.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 138
ADD08209
ID ADD08209 standard; protein; 90 AA.
XX
AC ADD08209;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.
XX
PN US2003068623-A1.
XX

PD 10-APR-2003.
XX
PF 14-NOV-2001; 2001US-00993469.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.

PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 139
ADD03299
ID ADD03299 standard; protein; 90 AA.
XX
AC ADD03299;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092104-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131817.
XX
PR 31-MAR-1997; 97WO-US005230.

PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801169/75.
DR N-PSDB; ADD03298.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in

CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 140
ADC90291
ID ADC90291 standard; protein; 90 AA.
XX
AC ADC90291;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087348-A1.
XX
PD 08-MAY-2003.
XX
PF 19-APR-2002; 2002US-00125923.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-786939/74.
DR N-PSDB; ADC90290.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; SEQ ID NO 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 141
ADC82034
ID ADC82034 standard; protein; 90 AA.
XX
AC ADC82034;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003083461-A1.
XX
PD 01-MAY-2003.
XX
PF 14-NOV-2001; 2001US-00992521.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.

PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.

PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 142
ADC69710
ID ADC69710 standard; protein; 90 AA.
XX
AC ADC69710;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194770-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152375.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844453/78.
DR N-PSDB; ADC69709.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 143
ADC48599
ID ADC48599 standard; protein; 90 AA.
XX
AC ADC48599;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;

KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194773-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152391.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-844455/78.
DR N-PSDB; ADC48598.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha and stimulating the proliferation of endothelial cells.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 144
ADD10128
ID ADD10128 standard; protein; 90 AA.
XX
AC ADD10128;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194776-A1.
XX
PD 16-OCT-2003.
XX
PF 29-MAY-2002; 2002US-00157785.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852596/79.
DR N-PSDB; ADD10127.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of proteoglycans from
PT cartilage and inhibiting the differentiation of adipocyte cells.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 145
ADD07676
ID ADD07676 standard; protein; 90 AA.
XX
AC ADD07676;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.
XX
PN US2002193299-A1.
XX
PD 19-DEC-2002.
XX
PF 19-NOV-2001; 2001US-00989735.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-657230/62.
DR N-PSDB; ADD07675.
XX
PT Isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346 and
PT PRO1375, which stimulate proliferation of stimulated T-lymphocytes and
PT are thus therapeutically useful e.g. for enhancing immune response.
XX
PS Claim 12; SEQ ID NO 377; 659pp; English.
XX
CC The invention relates to human secreted and transmembrane PRO
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,
CC inducing proliferation and/or re-differentiation of chondrocytes, or
CC inducing pancreatic beta-cell precursor differentiation into mature
CC pancreatic beta-cells. They may therefore be useful in the treatment of
CC various insulin deficient states in mammals, including diabetes mellitus,
CC and in treating undesired endothelial cell growth, e.g., inhibiting
CC tumour growth. The sequences are also useful for treating mammalian
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
CC renal dysplasia, polycystic kidney disease, renal tumours, and other
CC cancers such as those of the colon, lung and breast. PRO polypeptides or
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
CC a sample; to link a bioactive molecule to a cell; to modulate a
CC biological activity of a cell; as molecular weight markers for protein
CC electrophoresis purposes; for tissue typing; to prepare a medicament for
CC treating a condition responsive to the polypeptide or antibody, such as
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
CC disease); and in various diagnostic assays. The PRO polynucleotides can
CC be used as hybridisation probes, in chromosome and gene mapping, in
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
CC may also be used in preparing PRO polypeptides by recombinant techniques,
CC and in generating either transgenic animals or knock-out animals which,
CC in turn, are useful in the development and screening of therapeutically
CC useful reagents. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
||||||||||||||||||||||||||||||
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 146
ADD04703
ID ADD04703 standard; protein; 90 AA.
XX
AC ADD04703;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003087354-A1.
XX
PD 08-MAY-2003.
XX
PF 22-APR-2002; 2002US-00127827.
XX
PR 17-AUG-1998; 98US-0096891P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 30-MAY-2000; 2000WO-US014941.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801139/75.
DR N-PSDB; ADD04702.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are

```
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC   cells, for stimulating differentiation of adipocyte cells, for
CC   stimulating proliferation of or gene expression in pericyte cells, for
CC   stimulating the proliferation of inner ear utricular supporting cells or
CC   T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC   treating various bone and/or cartilage disorders such as sports injuries
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 147
ADC82567
ID   ADC82567 standard; protein; 90 AA.
XX
AC   ADC82567;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #118.
XX
KW   Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW   cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS   Homo sapiens.
XX
PN   US2003059833-A1.
XX
PD   27-MAR-2003.
XX
PF   15-NOV-2001; 2001US-00997440.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087106P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   19-JUN-1998;   98US-0089947P.
PR   19-JUN-1998;   98US-0089948P.
PR   19-JUN-1998;   98US-0089952P.
PR   22-JUN-1998;   98US-0090246P.
PR   22-JUN-1998;   98US-0090252P.
PR   22-JUN-1998;   98US-0090254P.
PR   23-JUN-1998;   98US-0090349P.
PR   23-JUN-1998;   98US-0090355P.
PR   24-JUN-1998;   98US-0090429P.
PR   24-JUN-1998;   98US-0090431P.
PR   24-JUN-1998;   98US-0090435P.
PR   24-JUN-1998;   98US-0090444P.
PR   24-JUN-1998;   98US-0090445P.
PR   24-JUN-1998;   98US-0090472P.
PR   24-JUN-1998;   98US-0090535P.
PR   24-JUN-1998;   98US-0090540P.
PR   24-JUN-1998;   98US-0090542P.
PR   24-JUN-1998;   98US-0090557P.
PR   25-JUN-1998;   98US-0090676P.
PR   25-JUN-1998;   98US-0090678P.
PR   25-JUN-1998;   98US-0090690P.
PR   25-JUN-1998;   98US-0090694P.
PR   25-JUN-1998;   98US-0090695P.
PR   25-JUN-1998;   98US-0090696P.
PR   26-JUN-1998;   98US-0090862P.
PR   26-JUN-1998;   98US-0090863P.
PR   01-JUL-1998;   98US-0091360P.
PR   01-JUL-1998;   98US-0091544P.
PR   02-JUL-1998;   98US-0091478P.
PR   02-JUL-1998;   98US-0091519P.
PR   02-JUL-1998;   98US-0091626P.
PR   02-JUL-1998;   98US-0091628P.
PR   02-JUL-1998;   98US-0091633P.
PR   02-JUL-1998;   98US-0091646P.
PR   02-JUL-1998;   98US-0091673P.
PR   07-JUL-1998;   98US-0091978P.
```

PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 20-FEB-1999; 99WO-US030911.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 148
ADC80659
ID ADC80659 standard; protein; 90 AA.
XX
AC ADC80659;
XX
DT 01-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092103-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131815.
XX
PR 22-DEC-1998; 98US-0113511P.
PR 01-DEC-1999; 99WO-US028634.
PR 22-FEB-2000; 2000WO-US004414.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-801168/75.
DR N-PSDB; ADC80658.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries
CC and arthritis. PRO polypeptides which stimulate the release of
CC proteoglycans from cartilage are useful for treating sports-related joint
CC problems, articular cartilage defects, osteoarthritis and rheumatoid
CC arthritis. PRO polypeptides are also useful for treating various
CC mammalian haemoglobin-associated disorders such as various thalassaemias
CC and conditions which may benefit from enhanced local immune system cell
CC infiltration. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 149
ADD11166
ID ADD11166 standard; protein; 90 AA.
XX
AC ADD11166;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194774-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152399.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852594/79.
DR N-PSDB; ADD11165.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the proliferation or differentiation
PT of chondrocyte cells and stimulating the release of tumor necrosis factor
PT alpha.
XX
PS Claim 12; SEQ ID NO 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

```
  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 150
ADC48047
ID   ADC48047 standard; protein; 90 AA.
XX
AC   ADC48047;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003194771-A1.
XX
PD   16-OCT-2003.
XX
PF   21-MAY-2002; 2002US-00152377.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Gurney SL,  Smith V;
PI   Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-844454/78.
DR   N-PSDB; ADC48046.
XX
PT   New secreted and transmembrane PRO polypeptides and nucleic acids useful
PT   for detecting a tumor, stimulating the release of proteoglycans from
PT   cartilage and stimulating the proliferation of endothelial cells.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 151
ADD08747
ID   ADD08747 standard; protein; 90 AA.
XX
AC   ADD08747;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted protein; transmembrane protein; PRO;
KW   neonatal heart hypertrophy; angiogenesis;
KW   vascular endothelial growth factor; VEGF-stimulated proliferation;
KW   endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW   rod photoreceptor cell; c-fos induction; adipocyte;
KW   chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW   breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW   Parkinson's disease; Alzheimer's disease; gene therapy;
KW   chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW   antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW   antiparkinsonian.
XX
OS   Homo sapiens.
XX
PN   US2003073090-A1.
XX
PD   17-APR-2003.
XX
PF   16-NOV-2001; 2001US-00990439.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
```

PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.

```
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 152
ADC80107
ID   ADC80107 standard; protein; 90 AA.
XX
AC   ADC80107;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW   transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW   chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW   rectum; kidney; cervix; liver; microvascular endothelial cell;
KW   glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW   cell differentiation; skeletal muscle cell; adipocyte cell;
KW   pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW   immune system cell infiltration; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003087358-A1.
XX
PD   08-MAY-2003.
XX
PF   22-APR-2002; 2002US-00127833.
XX
PR   01-SEP-1998;   98US-0098750P.
PR   01-SEP-1999;   99WO-US020111.
PR   18-OCT-1999;   99US-00403297.
PR   18-FEB-2000; 2000WO-US004342.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-801143/75.
DR   N-PSDB; ADC80106.
XX
PT   New PRO nucleic acid, useful for manufacturing a medicament for
PT   diagnosing or treating tumor.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC   cells, for stimulating differentiation of adipocyte cells, for
CC   stimulating proliferation of or gene expression in pericyte cells, for
CC   stimulating the proliferation of inner ear utricular supporting cells or
CC   T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC   treating various bone and/or cartilage disorders such as sports injuries
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 153
ADD06996
ID   ADD06996 standard; protein; 90 AA.
XX
AC   ADD06996;
XX
DT   01-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
```

KW Human; secreted protein; transmembrane protein; PRO;
KW neonatal heart hypertrophy; angiogenesis;
KW vascular endothelial growth factor; VEGF-stimulated proliferation;
KW endothelial cell; T-lymphocyte proliferation; retinal neuron;
KW rod photoreceptor cell; c-fos induction; adipocyte;
KW chondrocyte differentiation; cancer; tumour; colon cancer; lung cancer;
KW breast cancer; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; neurodegenerative disorder;
KW Parkinson's disease; Alzheimer's disease; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW antidiabetic; antianaemic; cytostatic; nootropic; neuroprotective;
KW antiparkinsonian.
XX
OS Homo sapiens.
XX
PN US2002193300-A1.
XX
PD 19-DEC-2002.
XX
PF 14-NOV-2001; 2001US-00990444.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 02-JUN-1999; 99WO-US012252.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 28-AUG-2001; 2001US-00941992.
XX
PA (GETH) GENENTECH INC.
XX
PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
PI Zhang Z;
XX
DR WPI; 2003-657231/62.
DR N-PSDB; ADD06995.
XX
PT Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
PT and are thus therapeutically useful for enhancing immune response.
XX
PS Claim 12; SEQ ID NO 377; 653pp; English.
XX
CC The invention relates to human secreted and transmembrane PRO
CC polypeptides and the polynucleotides encoding them. The PRO polypeptides
CC or polynucleotides are useful as pharmaceuticals, diagnostics, biosensors
CC or bioreactors. They are useful for stimulating hypertrophy of neonatal
CC heart, promoting angiogenesis, inhibiting vascular endothelial growth
CC factor (VEGF)-stimulated proliferation of endothelial cells, modulating
CC the proliferation of stimulated T-lymphocytes, enhancing the survival or
CC proliferation of retinal neurons or rod photoreceptor cells, inducing c-
CC fos in endothelial cells, modulating glucose or FFA uptake by adipocytes,
CC inducing proliferation and/or re-differentiation of chondrocytes, or
CC inducing pancreatic beta-cell precursor differentiation into mature
CC pancreatic beta-cells. They may therefore be useful in the treatment of

CC various insulin deficient states in mammals, including diabetes mellitus,
CC and in treating undesired endothelial cell growth, e.g., inhibiting
CC tumour growth. The sequences are also useful for treating mammalian
CC haemoglobin-associated disorders (e.g., various thalassaemias), cystic
CC renal dysplasia, polycystic kidney disease, renal tumours, and other
CC cancers such as those of the colon, lung and breast. PRO polypeptides or
CC antibodies to PRO polypeptides may be used to detect a PRO polypeptide in
CC a sample; to link a bioactive molecule to a cell; to modulate a
CC biological activity of a cell; as molecular weight markers for protein
CC electrophoresis purposes; for tissue typing; to prepare a medicament for
CC treating a condition responsive to the polypeptide or antibody, such as
CC neurodegenerative disorders (e.g., Parkinson's disease or Alzheimer's
CC disease); and in various diagnostic assays. The PRO polynucleotides can
CC be used as hybridisation probes, in chromosome and gene mapping, in
CC generating antisense RNA and DNA, and in gene therapy. The polynucleotide
CC may also be used in preparing PRO polypeptides by recombinant techniques,
CC and in generating either transgenic animals or knock-out animals which,
CC in turn, are useful in the development and screening of therapeutically
CC useful reagents. This sequence represents a human PRO polypeptide of the
CC invention. Note: The sequence data for this patent is also available in
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 154
ADD09576
ID ADD09576 standard; protein; 90 AA.
XX
AC ADD09576;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194775-A1.
XX
PD 16-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156848.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852595/79.
DR N-PSDB; ADD09575.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting a tumor, stimulating the release of tumor necrosis factor
PT alpha from blood and stimulating the release of proteoglycans from
PT cartilage.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 155
ADC83243
ID ADC83243 standard; protein; 90 AA.
XX
AC ADC83243;
XX
DT 01-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;

KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003059783-A1.
XX
PD 27-MAR-2003.
XX
PF 15-NOV-2001; 2001US-00997683.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.

```
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98US-0100858P.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   22-DEC-1998;   98US-0113296P.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   12-MAR-1999;   99US-0123957P.
PR   02-JUN-1999;   99WO-US012252.
PR   23-JUN-1999;   99US-0141037P.
PR   07-JUL-1999;   99US-0143048P.
PR   20-JUL-1999;   99US-0144758P.
PR   26-JUL-1999;   99US-0145698P.
PR   28-JUL-1999;   99US-0146222P.
PR   17-AUG-1999;   99US-0149396P.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   08-OCT-1999;   99US-0158663P.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.

  Query Match           100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 156
ADD41289
ID   ADD41289 standard; protein; 90 AA.
XX
AC   ADD41289;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inhibitor; cytokine release stimulator; tumour;
KW   lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003203438-A1.
XX
PD   30-OCT-2003.
XX
PF   15-MAY-2002; 2002US-00146786.
XX
PR   24-NOV-1997;   97US-0066511P.
PR   16-SEP-1998;   98WO-US019330.
PR   25-AUG-1999;   99US-00380139.
PR   22-FEB-2000; 2000WO-US004414.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-875645/81.
DR   N-PSDB; ADD41288.
XX
PT   New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT   PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT   generating antisense RNA and DNA, and in gene therapy.
XX
PS   Claim 12; SEQ ID NO 474; 637pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match           100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
```

```
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 157
ADD52428
ID   ADD52428 standard; protein; 90 AA.
XX
AC   ADD52428;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003194769-A1.
XX
PD   16-OCT-2003.
XX
PF   21-MAY-2002; 2002US-00152374.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-852593/79.
DR   N-PSDB; ADD52427.
XX
PT   New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT   acids, useful for detection of tumors, modulating the uptake of glucose
PT   or free fatty acids and stimulating the release of proteoglycans from
PT   cartilage.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   the USPTO website at seqdata.uspto.gov.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 158
ADD53168
ID   ADD53168 standard; protein; 90 AA.
XX
AC   ADD53168;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003194792-A1.
XX
PD   16-OCT-2003.
XX
PF   15-APR-2002; 2002US-00123156.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
```

PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852599/79.
DR N-PSDB; ADD53167.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in chromosome and gene mapping, in generating antisense
PT RNA and DNA, and in the treatment of cancer.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

```
Qy          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
               ||||||||||||||||||||||||||||||
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 159
ADD53720
ID ADD53720 standard; protein; 90 AA.
XX
AC ADD53720;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203437-A1.
XX
PD 30-OCT-2003.
XX
PF 15-MAY-2002; 2002US-00146728.
XX
PR 01-JUL-1998; 98US-0091360P.
PR 02-JUN-1999; 99WO-US012252.
PR 01-DEC-2000; 2000US-00380137.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875644/81.
DR N-PSDB; ADD53719.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; SEQ ID NO 474; 659pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

```
  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db           1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
               ||||||||||||||||||||||||||||||
Db          61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 160
ADD55350
ID ADD55350 standard; protein; 90 AA.
XX
AC ADD55350;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003077593-A1.
XX
PD 24-APR-2003.
XX
PF 19-NOV-2001; 2001US-00989328.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.

PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.

PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 161
ADD56308
ID ADD56308 standard; protein; 90 AA.
XX
AC ADD56308;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #118.
XX
KW Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS Homo sapiens.
XX
PN US2003077594-A1.
XX
PD 24-APR-2003.
XX
PF 14-NOV-2001; 2001US-00993583.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.

PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
||||||||||||||||||||||||||||||
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 162
ADD51876
ID ADD51876 standard; protein; 90 AA.
XX
AC ADD51876;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194779-A1.
XX
PD 16-OCT-2003.
XX
PF 30-MAY-2002; 2002US-00160500.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-852597/79.
DR N-PSDB; ADD51875.
XX
PT New secreted and transmembrane PRO nucleic acids and polypeptides, useful
PT for detecting the presence of a tumor, stimulating the release of tumor
PT necrosis factor alpha from human blood and treating, e.g. organ failure.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 163
ADD02675
ID ADD02675 standard; protein; 90 AA.
XX
AC ADD02675;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203431-A1.
XX
PD 30-OCT-2003.
XX
PF 24-APR-2002; 2002US-00131820.
XX
PR 28-OCT-1998; 98US-0106030P.
PR 01-SEP-1999; 99WO-US020111.
PR 18-OCT-1999; 99US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-AUG-2000; 2000WO-US023328.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875638/81.
DR N-PSDB; ADD02674.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 164

ADD02109
ID ADD02109 standard; protein; 90 AA.
XX
AC ADD02109;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203430-A1.
XX
PD 30-OCT-2003.
XX
PF 23-APR-2002; 2002US-00128685.
XX
PR 11-AUG-1998; 98US-0096143P.
PR 02-JUN-1999; 99WO-US012252.
PR 30-MAR-2000; 2000US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875637/81.
DR N-PSDB; ADD02108.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 165
ADD54291
ID ADD54291 standard; protein; 90 AA.
XX
AC ADD54291;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003203432-A1.
XX
PD 30-OCT-2003.
XX
PF 10-MAY-2002; 2002US-00142886.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875639/81.
DR N-PSDB; ADD54290.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; SEQ ID NO 474; 637pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and

```
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 166
ADD54746
ID   ADD54746 standard; protein; 90 AA.
XX
AC   ADD54746;
XX
DT   15-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #118.
XX
KW   Human; PRO; pancreatic beta-cell precursor cell; pancreatic beta-cell;
KW   insulin deficiency; diabetes mellitus; haemoglobin-associated disorder;
KW   thalassaemia; endothelial cell growth; cancer; cystic renal dysplasia;
KW   polycystic kidney disease; renal tumour; antidiabetic; antianaemic;
KW   cytostatic; cardiant; vulnerary; antiinflammatory; anorectic.
XX
OS   Homo sapiens.
XX
PN   US2002132253-A1.
XX
PD   19-SEP-2002.
XX
PF   14-NOV-2001; 2001US-00991163.
XX
PR   16-JUN-1997;   97US-0049787P.
PR   17-OCT-1997;   97US-0062250P.
PR   05-NOV-1997;   97WO-US020069.
PR   12-NOV-1997;   97US-0065186P.
PR   13-NOV-1997;   97US-0065311P.
PR   24-NOV-1997;   97US-0066770P.
PR   25-FEB-1998;   98US-0075945P.
PR   20-MAR-1998;   98US-0078910P.
PR   28-APR-1998;   98US-0083322P.
PR   07-MAY-1998;   98US-0084600P.
PR   28-MAY-1998;   98US-0087105P.
PR   02-JUN-1998;   98US-0087607P.
PR   02-JUN-1998;   98US-0087609P.
PR   02-JUN-1998;   98US-0087759P.
PR   03-JUN-1998;   98US-0087827P.
PR   04-JUN-1998;   98US-0088021P.
PR   04-JUN-1998;   98US-0088025P.
PR   04-JUN-1998;   98US-0088026P.
PR   04-JUN-1998;   98US-0088028P.
PR   04-JUN-1998;   98US-0088029P.
PR   04-JUN-1998;   98US-0088030P.
PR   04-JUN-1998;   98US-0088033P.
PR   04-JUN-1998;   98US-0088326P.
PR   05-JUN-1998;   98US-0088167P.
PR   05-JUN-1998;   98US-0088202P.
PR   05-JUN-1998;   98US-0088212P.
PR   05-JUN-1998;   98US-0088217P.
PR   09-JUN-1998;   98US-0088655P.
PR   10-JUN-1998;   98US-0088734P.
PR   10-JUN-1998;   98US-0088738P.
PR   10-JUN-1998;   98US-0088742P.
PR   10-JUN-1998;   98US-0088810P.
PR   10-JUN-1998;   98US-0088824P.
PR   10-JUN-1998;   98US-0088826P.
PR   11-JUN-1998;   98US-0088858P.
PR   11-JUN-1998;   98US-0088861P.
PR   11-JUN-1998;   98US-0088876P.
PR   12-JUN-1998;   98US-0089105P.
PR   16-JUN-1998;   98US-0089440P.
PR   16-JUN-1998;   98US-0089512P.
PR   16-JUN-1998;   98US-0089514P.
PR   17-JUN-1998;   98US-0089532P.
PR   17-JUN-1998;   98US-0089538P.
PR   17-JUN-1998;   98US-0089598P.
PR   17-JUN-1998;   98US-0089599P.
PR   17-JUN-1998;   98US-0089600P.
PR   17-JUN-1998;   98US-0089653P.
PR   18-JUN-1998;   98US-0089801P.
PR   18-JUN-1998;   98US-0089907P.
PR   18-JUN-1998;   98US-0089908P.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   02-JUN-1999;   99WO-US012252.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   30-NOV-1999;   99WO-US028313.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   06-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
```

```
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   01-DEC-2000; 2000WO-US032678.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-JUN-2001; 2001WO-US017800.
PR   20-JUN-2001; 2001WO-US019692.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   28-AUG-2001; 2001US-00941992.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Baker KP,  Botstein D,  Desnoyers L,  Eaton DL;
PI   Ferrara N,  Fong S,  Gerber H,  Gerritsen ME,  Goddard A,  Godowski PJ;
PI   Grimaldi JC,  Gurney AL,  Kljavin IJ,  Napier MA,  Pan J,  Paoni NF;
PI   Roy MA,  Stewart TA,  Tumas D,  Watanabe CK,  Williams PM,  Wood WI;
PI   Zhang Z;
XX
DR   WPI; 2003-695825/66.
DR   N-PSDB; ADD54745.
XX
PT   New PRO polypeptides and nucleic acid molecules, useful in gene therapy,
PT   or in diagnosing or treating inflammatory diseases, diabetes, cancer,
PT   rheumatoid arthritis, ulcers, amyotrophic lateral sclerosis or septic
PT   shock.
XX
PS   Claim 12; SEQ ID NO 377; 658pp; English.
XX
CC   The invention relates to human PRO polypeptides and the polynucleotides
CC   encoding them. The sequences are useful for inducing differentiation of
CC   pancreatic beta-cell precursor cells into mature pancreatic beta-cells,
CC   and thus for treating various insulin deficient states in mammals,
CC   including diabetes mellitus. The sequences are also useful for treating
CC   mammalian haemoglobin-associated disorders e.g., various thalassaemias,
CC   undesired endothelial cell growth e.g., inhibiting tumour growth, cystic
CC   renal dysplasia, polycystic kidney disease and renal tumours. The
CC   polypeptides are useful for tissue typing, as molecular weight markers
CC   for protein electrophoresis purposes, as therapeutic agents and as
CC   hybridisation probes for isolating PRO cDNA from a cDNA library. The
CC   polynucleotides are useful in gene therapy, as chromosome identification
CC   recombinantly expressing molecular weight markers, in chromosome and gene
CC   mapping, in the generation of anti-sense RNA and DNA and in preparation
CC   of PRO polypeptides by recombinant techniques. This sequence represents a
CC   human PRO polypeptide of the invention. Note: The sequence data for this
CC   patent is also available in electronic format from USPTO at
CC   seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 167
ADD92608
ID   ADD92608 standard; protein; 90 AA.
XX
AC   ADD92608;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199030-A1.
XX
PD   23-OCT-2003.
XX
PF   28-MAY-2002; 2002US-00156841.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-900159/82.
DR   N-PSDB; ADD92607.
XX
PT   Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT   useful for treating pericyte-associated tumors, diabetes and various bone
PT   and/or cartilage disorders, e.g. arthritis.
XX
PS   Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
```

```
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTPFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTPFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 168
ADD91504
ID   ADD91504 standard; protein; 90 AA.
XX
AC   ADD91504;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199055-A1.
XX
PD   23-OCT-2003.
XX
PF   12-APR-2002; 2002US-00121063.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
```

```
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2003-900165/82.
DR   N-PSDB; ADD91503.
XX
PT   Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT   useful for treating pericyte-associated tumors, diabetes and various bone
PT   and/or cartilage disorders, e.g. arthritis.
XX
PS   Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 169
ADE04118
ID   ADE04118 standard; protein; 90 AA.
XX
AC   ADE04118;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199057-A1.
XX
PD   23-OCT-2003.
XX
PF   15-APR-2002; 2002US-00123213.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
```

PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900167/82.
DR N-PSDB; ADE04117.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 170
ADE26900
ID ADE26900 standard; protein; 90 AA.
XX
AC ADE26900;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003087304-A1.
XX
PD 08-MAY-2003.
XX
PF 15-NOV-2001; 2001US-00997333.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.

PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.
PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025103.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000105.
PR 20-FEB-1999; 99WO-US030911.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.

```
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   30-MAR-2000; 2000WO-US008439.
PR   15-MAY-2000; 2000WO-US013358.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   23-JUN-2000; 2000US-0213637P.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   07-SEP-2000; 2000US-0230978P.

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 171
ADE32415
ID   ADE32415 standard; protein; 90 AA.
XX
AC   ADE32415;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Novel human secreted and transmembrane protein PRO1159.
XX
KW   Human; secreted and transmembrane protein; PRO;
KW   Tumour necrosis factor alpha release; TNF-alpha release;
KW   glucose uptake modulator; FFA uptake modulator;
KW   cell proliferation stimulator; cell differentiation stimulator;
KW   cell differentiation inhibitor; cytokine release stimulator; tumour;
KW   lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW   cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW   gene therapy; chromosome identification; chromosome marker.
XX
OS   Homo sapiens.
XX
PN   US2003194765-A1.
XX
PD   16-OCT-2003.
XX
PF   09-MAY-2002; 2002US-00142889.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-899784/82.
DR   N-PSDB; ADE32414.
XX
PT   Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT   useful for treating pericyte-associated tumors, diabetes and various bone
PT   and/or cartilage disorders, e.g. arthritis.
XX
PS   Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC   The invention describes 305 nucleic acids encoding PRO (secreted and
CC   transmembrane) polypeptides (I). (I) is useful for stimulating the
CC   release of TNF-alpha from human blood, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating the proliferation or differentiation of chondrocyte cells,
CC   for stimulating the proliferation of or gene expression in pericyte
CC   cells, for stimulating the release of proteoglycans from cartilage, for
CC   stimulating the proliferation of inner ear utricular supporting cells,
CC   for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC   the release of a cytokine from PBMC cells, for inhibiting the binding of
CC   A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC   cells, for stimulating proliferation of endothelial cells, for detecting
CC   the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC   prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC   are useful for isolating genomic and cDNA nucleotide sequences or
CC   antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC   in assays to identify other proteins or molecules involved in binding
CC   interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC   and gene mapping, in generation of antisense RNA and DNA, in the
CC   preparation of PRO polypeptide, for generating transgenic animals or
CC   knockout animals which in turn are useful in the development and
CC   screening of therapeutically useful reagents, in gene therapy, for
CC   chromosome identification, as chromosome marker, and for generating
CC   probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC   detecting its expression in specific cells, tissues or serum, and for
CC   affinity purification of PRO from recombinant cell culture or natural
CC   sources. (I) and (II) are useful for tissue typing. This is the amino
CC   acid sequence of a novel human secreted and transmembrane PRO
CC   polypeptide.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 172
ADE22347
ID   ADE22347 standard; protein; 90 AA.
XX
AC   ADE22347;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
```

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199056-A1.
XX
PD 23-OCT-2003.
XX
PF 15-APR-2002; 2002US-00123212.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900166/82.
DR N-PSDB; ADE22346.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 173
ADD79571
ID ADD79571 standard; protein; 90 AA.
XX
AC ADD79571;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203428-A1.
XX
PD 30-OCT-2003.
XX
PF 22-APR-2002; 2002US-00127852.
XX
PR 09-DEC-1999; 99US-0170262P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875635/81.
DR N-PSDB; ADD79570.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 174
ADE42107
ID ADE42107 standard; protein; 90 AA.
XX
AC ADE42107;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194772-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152386.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899788/82.
DR N-PSDB; ADE42106.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 175
ADE17924
ID ADE17924 standard; protein; 90 AA.
XX
AC ADE17924;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199023-A1.
XX
PD 23-OCT-2003.
XX
PF 17-APR-2002; 2002US-00124821.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900155/82.
DR N-PSDB; ADE17923.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; SEQ ID NO 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 176
ADD92056
ID ADD92056 standard; protein; 90 AA.
XX
AC ADD92056;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX

OS Homo sapiens.
XX
PN US2003199053-A1.
XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121053.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900164/82.
DR N-PSDB; ADD92055.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 177
ADE33519
ID ADE33519 standard; protein; 90 AA.
XX
AC ADE33519;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003194767-A1.
XX
PD 16-OCT-2003.
XX
PF 16-MAY-2002; 2002US-00147497.
XX
PR 26-AUG-1998; 98US-0097951P.
PR 02-JUN-1999; 99WO-US012252.
PR 25-AUG-1999; 99US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899786/82.
DR N-PSDB; ADE33518.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 178
ADE34071
ID ADE34071 standard; protein; 90 AA.
XX
AC ADE34071;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003194791-A1.
XX
PD 16-OCT-2003.
XX
PF 11-APR-2002; 2002US-00121046.

XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899790/82.
DR N-PSDB; ADE34070.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX

```
SQ   Sequence 90 AA;

  Query Match            100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 179
ADD80123
ID   ADD80123 standard; protein; 90 AA.
XX
AC   ADD80123;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003207417-A1.
XX
PD   06-NOV-2003.
XX
PF   07-MAY-2002; 2002US-00140805.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
```

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875867/81.
DR N-PSDB; ADD80122.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 180
ADD93160
ID ADD93160 standard; protein; 90 AA.
XX
AC ADD93160;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194768-A1.
XX
PD 16-OCT-2003.
XX
PF 21-MAY-2002; 2002US-00152371.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899787/82.
DR N-PSDB; ADD93159.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

```
  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 181
ADE19580
ID   ADE19580 standard; protein; 90 AA.
XX
AC   ADE19580;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199025-A1.
XX
PD   23-OCT-2003.
XX
PF   21-MAY-2002; 2002US-00152385.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-900156/82.
DR   N-PSDB; ADE19579.
XX
PT   Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT   useful for treating pericyte-associated tumors, diabetes and various bone
PT   and/or cartilage disorders, e.g. arthritis.
XX
PS   Claim 12; SEQ ID NO 474; 648pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 182
ADE19028
ID   ADE19028 standard; protein; 90 AA.
XX
AC   ADE19028;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199026-A1.
XX
PD   23-OCT-2003.
XX
PF   20-MAY-2002; 2002US-00152393.
XX
PR   03-MAR-2000; 2000US-0187202P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
```

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900157/82.
DR N-PSDB; ADE19027.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 183
ADE43224
ID ADE43224 standard; protein; 90 AA.
XX
AC ADE43224;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199033-A1.
XX
PD 23-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156845.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900162/82.
DR N-PSDB; ADE43223.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

```
  Query Match           100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity  100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 184
ADD96013
ID   ADD96013 standard; protein; 90 AA.
XX
AC   ADD96013;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199059-A1.
XX
PD   23-OCT-2003.
XX
PF   15-APR-2002; 2002US-00123322.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
```

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900168/82.
DR N-PSDB; ADD96012.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 185
ADE22899
ID ADE22899 standard; protein; 90 AA.
XX
AC ADE22899;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199064-A1.
XX
PD 23-OCT-2003.
XX
PF 19-APR-2002; 2002US-00125932.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.

PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900169/82.
DR N-PSDB; ADE22898.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 186
ADD79017
ID ADD79017 standard; protein; 90 AA.
XX
AC ADD79017;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203429-A1.
XX
PD 30-OCT-2003.
XX
PF 22-APR-2002; 2002US-00127900.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX

DR WPI; 2003-875636/81.
DR N-PSDB; ADD79016.
XX
PT New isolated, secreted and transmembrane PRO polypeptides and nucleic
PT acids, useful for the diagnosis, prevention and/or treatment of tumors,
PT such as lung, colon, breast, prostate, rectal, cervical and/or liver
PT tumors.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 187
ADE26367
ID ADE26367 standard; protein; 90 AA.
XX
AC ADE26367;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW human; secreted and transmembrane protein; PRO; nootropic;
KW neuroprotective; antiparkinsonian; cytostatic; gene therapy;
KW chromosome mapping; gene mapping; transgenic animal; knock-out animal;
KW neurodegenerative disorder; Parkinson's disease; Alzheimer's disease.
XX
OS Homo sapiens.
XX
PN US2003087305-A1.
XX
PD 08-MAY-2003.
XX
PF 15-NOV-2001; 2001US-00997384.
XX
PR 16-JUN-1997; 97US-0049787P.
PR 17-OCT-1997; 97US-0062250P.
PR 05-NOV-1997; 97WO-US020069.
PR 12-NOV-1997; 97US-0065186P.
PR 13-NOV-1997; 97US-0065311P.
PR 24-NOV-1997; 97US-0066770P.
PR 25-FEB-1998; 98US-0075945P.
PR 20-MAR-1998; 98US-0078910P.
PR 28-APR-1998; 98US-0083322P.
PR 07-MAY-1998; 98US-0084600P.
PR 28-MAY-1998; 98US-0087106P.
PR 02-JUN-1998; 98US-0087607P.
PR 02-JUN-1998; 98US-0087609P.
PR 02-JUN-1998; 98US-0087759P.
PR 03-JUN-1998; 98US-0087827P.
PR 04-JUN-1998; 98US-0088021P.
PR 04-JUN-1998; 98US-0088025P.
PR 04-JUN-1998; 98US-0088026P.
PR 04-JUN-1998; 98US-0088028P.
PR 04-JUN-1998; 98US-0088029P.
PR 04-JUN-1998; 98US-0088030P.
PR 04-JUN-1998; 98US-0088033P.
PR 04-JUN-1998; 98US-0088326P.
PR 05-JUN-1998; 98US-0088167P.
PR 05-JUN-1998; 98US-0088202P.
PR 05-JUN-1998; 98US-0088212P.
PR 05-JUN-1998; 98US-0088217P.
PR 09-JUN-1998; 98US-0088655P.
PR 10-JUN-1998; 98US-0088734P.
PR 10-JUN-1998; 98US-0088738P.
PR 10-JUN-1998; 98US-0088742P.
PR 10-JUN-1998; 98US-0088810P.
PR 10-JUN-1998; 98US-0088824P.
PR 10-JUN-1998; 98US-0088826P.
PR 11-JUN-1998; 98US-0088858P.
PR 11-JUN-1998; 98US-0088861P.
PR 11-JUN-1998; 98US-0088876P.
PR 12-JUN-1998; 98US-0089105P.
PR 16-JUN-1998; 98US-0089440P.
PR 16-JUN-1998; 98US-0089512P.
PR 16-JUN-1998; 98US-0089514P.
PR 17-JUN-1998; 98US-0089532P.
PR 17-JUN-1998; 98US-0089538P.
PR 17-JUN-1998; 98US-0089598P.
PR 17-JUN-1998; 98US-0089599P.
PR 17-JUN-1998; 98US-0089600P.
PR 17-JUN-1998; 98US-0089653P.
PR 18-JUN-1998; 98US-0089801P.
PR 18-JUN-1998; 98US-0089907P.
PR 18-JUN-1998; 98US-0089908P.
PR 19-JUN-1998; 98US-0089947P.
PR 19-JUN-1998; 98US-0089948P.
PR 19-JUN-1998; 98US-0089952P.
PR 22-JUN-1998; 98US-0090246P.
PR 22-JUN-1998; 98US-0090252P.
PR 22-JUN-1998; 98US-0090254P.
PR 23-JUN-1998; 98US-0090349P.
PR 23-JUN-1998; 98US-0090355P.
PR 24-JUN-1998; 98US-0090429P.
PR 24-JUN-1998; 98US-0090431P.
PR 24-JUN-1998; 98US-0090435P.
PR 24-JUN-1998; 98US-0090444P.
PR 24-JUN-1998; 98US-0090445P.
PR 24-JUN-1998; 98US-0090472P.

PR 24-JUN-1998; 98US-0090535P.
PR 24-JUN-1998; 98US-0090540P.
PR 24-JUN-1998; 98US-0090542P.
PR 24-JUN-1998; 98US-0090557P.
PR 25-JUN-1998; 98US-0090676P.
PR 25-JUN-1998; 98US-0090678P.
PR 25-JUN-1998; 98US-0090690P.
PR 25-JUN-1998; 98US-0090694P.
PR 25-JUN-1998; 98US-0090695P.
PR 25-JUN-1998; 98US-0090696P.
PR 26-JUN-1998; 98US-0090862P.
PR 26-JUN-1998; 98US-0090863P.
PR 01-JUL-1998; 98US-0091360P.
PR 01-JUL-1998; 98US-0091544P.
PR 02-JUL-1998; 98US-0091478P.
PR 02-JUL-1998; 98US-0091519P.
PR 02-JUL-1998; 98US-0091626P.
PR 02-JUL-1998; 98US-0091628P.
PR 02-JUL-1998; 98US-0091633P.
PR 02-JUL-1998; 98US-0091646P.
PR 02-JUL-1998; 98US-0091673P.
PR 07-JUL-1998; 98US-0091978P.
PR 07-JUL-1998; 98US-0091982P.
PR 09-JUL-1998; 98US-0092182P.
PR 10-JUL-1998; 98US-0092472P.
PR 20-JUL-1998; 98US-0093339P.
PR 30-JUL-1998; 98US-0094651P.
PR 04-AUG-1998; 98US-0095282P.
PR 04-AUG-1998; 98US-0095285P.
PR 04-AUG-1998; 98US-0095301P.
PR 04-AUG-1998; 98US-0095302P.
PR 04-AUG-1998; 98US-0095318P.
PR 04-AUG-1998; 98US-0095321P.
PR 04-AUG-1998; 98US-0095325P.
PR 10-AUG-1998; 98US-0095916P.
PR 10-AUG-1998; 98US-0095929P.
PR 10-AUG-1998; 98US-0096012P.
PR 11-AUG-1998; 98US-0096143P.
PR 11-AUG-1998; 98US-0096146P.
PR 12-AUG-1998; 98US-0096329P.
PR 17-AUG-1998; 98US-0096757P.
PR 17-AUG-1998; 98US-0096766P.
PR 17-AUG-1998; 98US-0096768P.
PR 17-AUG-1998; 98US-0096773P.
PR 17-AUG-1998; 98US-0096791P.
PR 17-AUG-1998; 98US-0096867P.
PR 17-AUG-1998; 98US-0096891P.
PR 17-AUG-1998; 98US-0096894P.
PR 17-AUG-1998; 98US-0096895P.
PR 17-AUG-1998; 98US-0096897P.
PR 18-AUG-1998; 98US-0096949P.
PR 18-AUG-1998; 98US-0096950P.
PR 18-AUG-1998; 98US-0096959P.
PR 18-AUG-1998; 98US-0096960P.
PR 18-AUG-1998; 98US-0097022P.
PR 19-AUG-1998; 98US-0097141P.
PR 20-AUG-1998; 98US-0097218P.
PR 24-AUG-1998; 98US-0097661P.
PR 26-AUG-1998; 98US-0097952P.
PR 26-AUG-1998; 98US-0097954P.
PR 26-AUG-1998; 98US-0097955P.
PR 26-AUG-1998; 98US-0097971P.
PR 26-AUG-1998; 98US-0097974P.
PR 26-AUG-1998; 98US-0097978P.
PR 26-AUG-1998; 98US-0097979P.
PR 26-AUG-1998; 98US-0097986P.
PR 26-AUG-1998; 98US-0098014P.
PR 31-AUG-1998; 98US-0098525P.
PR 16-SEP-1998; 98US-0100634P.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98US-0100858P.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 01-DEC-1998; 98WO-US025108.
PR 22-DEC-1998; 98US-0113296P.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 12-MAR-1999; 99US-0123957P.
PR 02-JUN-1999; 99WO-US012252.
PR 23-JUN-1999; 99US-0141037P.
PR 07-JUL-1999; 99US-0143048P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 28-JUL-1999; 99US-0146222P.
PR 17-AUG-1999; 99US-0149396P.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 08-OCT-1999; 99US-0158663P.
PR 30-NOV-1999; 99WO-US028313.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 30-MAR-2000; 2000WO-US008439.
PR 15-MAY-2000; 2000WO-US013358.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000US-0213637P.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 188
ADE32967
ID ADE32967 standard; protein; 90 AA.
XX
AC ADE32967;
XX
DT 29-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO;
KW Tumour necrosis factor alpha release; TNF-alpha release;
KW glucose uptake modulator; FFA uptake modulator;
KW cell proliferation stimulator; cell differentiation stimulator;
KW cell differentiation inhibitor; cytokine release stimulator; tumour;
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;

KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003194766-A1.
XX
PD 16-OCT-2003.
XX
PF 14-MAY-2002; 2002US-00145874.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-899785/82.
DR N-PSDB; ADE32966.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; SEQ ID NO 474; 636pp; English.
XX
CC The invention describes 305 nucleic acids encoding PRO (secreted and
CC transmembrane) polypeptides (I). (I) is useful for stimulating the
CC release of TNF-alpha from human blood, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating the proliferation or differentiation of chondrocyte cells,
CC for stimulating the proliferation of or gene expression in pericyte
CC cells, for stimulating the release of proteoglycans from cartilage, for
CC stimulating the proliferation of inner ear utricular supporting cells,
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating
CC the release of a cytokine from PBMC cells, for inhibiting the binding of
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
CC cells, for stimulating proliferation of endothelial cells, for detecting
CC the presence of tumour in a mammal. The tumour is lung, colon, breast,
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This is the amino
CC acid sequence of a novel human secreted and transmembrane PRO
CC polypeptide.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 189
ADE42659
ID ADE42659 standard; protein; 90 AA.
XX
AC ADE42659;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199032-A1.
XX
PD 23-OCT-2003.
XX
PF 28-MAY-2002; 2002US-00156844.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900161/82.
DR N-PSDB; ADE42658.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 636pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and

```
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 190
ADD80675
ID   ADD80675 standard; protein; 90 AA.
XX
AC   ADD80675;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003207418-A1.
XX
PD   06-NOV-2003.
XX
PF   07-MAY-2002; 2002US-00140809.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019632.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
```

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-875868/81.
DR N-PSDB; ADD80674.
XX
PT New PRO nucleic acid, useful for manufacturing a medicament for
PT diagnosing or treating tumor, for chromosome mapping or for tissue
PT typing.
XX
PS Claim 12; Fig 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 191

ADD89703
ID ADD89703 standard; protein; 90 AA.
XX
AC ADD89703;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199028-A1.
XX
PD 23-OCT-2003.
XX
PF 22-MAY-2002; 2002US-00153552.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900158/82.
DR N-PSDB; ADD89702.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

```
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 192
ADE40987
ID   ADE40987 standard; protein; 90 AA.
XX
AC   ADE40987;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199031-A1.
XX
PD   23-OCT-2003.
XX
PF   28-MAY-2002; 2002US-00156842.
XX
PR   05-JUN-2000; 2000US-0209832P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP,  Beresini M,  Deforge L,  Desnoyers L,  Filvaroff E,  Gao W;
PI   Gerritsen ME,  Goddard A,  Godowski PJ,  Gurney AL,  Sherwood S;
PI   Smith V,  Stewart TA,  Tumas D,  Watanabe CK,  Wood WI,  Zhang Z;
XX
DR   WPI; 2003-900160/82.
DR   N-PSDB; ADE40986.
XX
PT   Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT   useful for treating pericyte-associated tumors, diabetes and various bone
PT   and/or cartilage disorders, e.g. arthritis.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 7;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 193
ADE04786
ID   ADE04786 standard; protein; 90 AA.
XX
AC   ADE04786;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199034-A1.
XX
PD   23-OCT-2003.
```

XX
PF 28-MAY-2001; 2001US-00156846.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2003-900163/82.
DR N-PSDB; ADE04785.
XX
PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,
PT useful for treating pericyte-associated tumors, diabetes and various bone
PT and/or cartilage disorders, e.g. arthritis.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 7; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 194
ADC81211

ID ADC81211 standard; protein; 90 AA.
XX
AC ADC81211;
XX
DT 15-JAN-2004 (first entry)
XX
DE Novel human secreted and transmembrane protein PRO1159.
XX
KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;
KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;
KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;
KW rectum; kidney; cervix; liver; microvascular endothelial cell;
KW glucose uptake modulator; FFA uptake modulator; cell proliferation;
KW cell differentiation; skeletal muscle cell; adipocyte cell;
KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;
KW immune system cell infiltration; chromosome mapping; gene mapping;
KW gene therapy; chromosome identification; chromosome marker.
XX
OS Homo sapiens.
XX
PN US2003092115-A1.
XX
PD 15-MAY-2003.
XX
PF 30-MAY-2002; 2002US-00158785.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-020238/02.
DR N-PSDB; ADC81210.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte
CC cells, for stimulating differentiation of adipocyte cells, for
CC stimulating proliferation of or gene expression in pericyte cells, for
CC stimulating the proliferation of inner ear utricular supporting cells or
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for
CC treating various bone and/or cartilage disorders such as sports injuries

```
CC   and arthritis. PRO polypeptides which stimulate the release of
CC   proteoglycans from cartilage are useful for treating sports-related joint
CC   problems, articular cartilage defects, osteoarthritis and rheumatoid
CC   arthritis. PRO polypeptides are also useful for treating various
CC   mammalian haemoglobin-associated disorders such as various thalassaemias
CC   and conditions which may benefit from enhanced local immune system cell
CC   infiltration. This sequence represents a human PRO polypeptide of the
CC   invention. Note: The sequence data for this patent is also available in
CC   electronic format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 8;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 195
ADD76659
ID   ADD76659 standard; protein; 90 AA.
XX
AC   ADD76659;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003100087-A1.
XX
PD   29-MAY-2003.
XX
PF   16-APR-2002; 2002US-00123912.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   10-MAR-2000; 2000WO-US006319.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
PR   20-JUN-2001; 2001WO-US019692.
PR   21-JUN-2001; 2001US-00887879.
PR   22-JUN-2001; 2001WO-US020116.
```

```
PR   29-JUN-2001; 2001WO-US021066.
PR   09-JUL-2001; 2001WO-US021735.
PR   18-JUL-2001; 2001US-00908827.
PR   06-AUG-2001; 2001US-00924419.
PR   09-AUG-2001; 2001US-00927796.
PR   16-AUG-2001; 2001US-00931836.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2004-008956/01.
DR   N-PSDB; ADD76658.
XX
PT   New PRO nucleic acid, useful for recombinantly producing a PRO
PT   polypeptide and for manufacturing a medicament for diagnosing or treating
PT   a tumor.
XX
PS   Claim 12; Fig 474; 638pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 8;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 196
ADD88023
ID   ADD88023 standard; protein; 90 AA.
XX
AC   ADD88023;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003092113-A1.
XX
PD   15-MAY-2003.
XX
PF   16-MAY-2002; 2002US-00147523.
XX
PR   09-DEC-1999;   99US-0170262P.
PR   01-DEC-2000; 2000WO-US032678.
PR   19-DEC-2001; 2001US-00028072.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI   Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI   Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR   WPI; 2004-020237/02.
DR   N-PSDB; ADD88022.
XX
PT   New secreted and transmembrane nucleic acids and polypeptides, designated
PT   as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT   cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT   cancer.
XX
PS   Claim 12; Fig 474; 637pp; English.
XX
CC   The invention relates to isolated human PRO polypeptides (secreted and
CC   transmembrane polypeptides) and the polynucleotides encoding them. The
CC   invention also relates to an antibody which specifically binds to a PRO
CC   polypeptide, a method for stimulating the release of tumour necrosis
CC   factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC   proliferation or differentiation of chondrocyte cells and a method for
CC   detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC   colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC   polynucleotides are useful in molecular biology, including uses as
CC   hybridisation probes, in chromosome and gene mapping, in generating
CC   antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC   be used in preparing PRO polypeptides by recombinant techniques and in
CC   generating either transgenic animals or knock-out animals which are
CC   useful in the development and screening of therapeutically useful
CC   reagents. The PRO polypeptides or antibodies are used in preparing a
CC   medicament for treating a condition responsive to the polypeptides or
CC   antibodies, such as tumours, for stimulating and inhibiting proliferation
CC   of human microvascular endothelial cells, for modulating the uptake of
CC   glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC   stimulating differentiation of adipocyte cells, for stimulating
CC   proliferation of or gene expression in pericyte cells, for stimulating
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
```

CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 197
ADD86427
ID ADD86427 standard; protein; 90 AA.
XX
AC ADD86427;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203440-A1.
XX
PD 30-OCT-2003.
XX
PF 29-MAY-2002; 2002US-00157798.
XX
PR 05-JUN-2000; 2000US-0209832P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-021363/02.
DR N-PSDB; ADD86426.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 198
ADE75875
ID ADE75875 standard; protein; 90 AA.
XX
AC ADE75875;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003211571-A1.
XX

PD 13-NOV-2003.
XX
PF 20-MAY-2002; 2002US-00152405.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-051576/05.
DR N-PSDB; ADE75874.
XX
PT New secreted and transmembrane PRO polypeptide and nucleic acid encoding
PT it, for use in gene therapy, as diagnostic markers for the presence of a
PT disease condition, or as therapeutic targets for treating tumors,
PT diabetes, or arthritis.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 199
ADE23451
ID ADE23451 standard; protein; 90 AA.
XX
AC ADE23451;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003092108-A1.
XX
PD 15-MAY-2003.
XX
PF 24-APR-2002; 2002US-00131835.
XX
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-020234/02.
DR N-PSDB; ADE23450.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 200
ADE24003
ID ADE24003 standard; protein; 90 AA.
XX
AC ADE24003;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003092110-A1.
XX
PD 15-MAY-2003.
XX
PF 03-MAY-2002; 2002US-00137864.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-020235/02.
DR N-PSDB; ADE24002.
XX
PT New secreted and transmembrane nucleic acids and polypeptides, designated
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or
PT cancer.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polypeptide of the invention. Note: The sequence data for this patent is also available in electronic format from the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 201
ADE24646
ID ADE24646 standard; protein; 90 AA.
XX
AC ADE24646;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003092111-A1.

XX
PD 15-MAY-2003.
XX
PF 03-MAY-2002; 2002US-00137869.
XX
PR 03-MAR-2000; 2000US-0187202P.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-020236/02.
DR N-PSDB; ADE24645.
XX
PT New secreted and transmembrane nucleic acid useful for treating
PT inflammation, organ failure, atherosclerosis, cardiac injury,
PT infertility, birth defects, premature aging, acquired immunodeficiency
PT syndrome, or cancer.
XX
PS Claim 12; Fig 474; 637pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC the USPTO website at seqdata.uspto.gov.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 202
ADD87471
ID ADD87471 standard; protein; 90 AA.
XX
AC ADD87471;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003203439-A1.
XX
PD 30-OCT-2003.
XX
PF 17-MAY-2002; 2002US-00147499.
XX
PR 04-AUG-1998; 98US-0095301P.
PR 02-JUN-1999; 99WO-US012252.
PR 30-MAR-2000; 2000US-00380137.
PR 30-MAR-2000; 2000WO-US008439.
PR 01-DEC-2000; 2000WO-US032678.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-021362/02.
DR N-PSDB; ADD87470.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; Fig 474; 648pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating

```
CC   the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC   cells, for inducing endothelial cell tube formation and for treating
CC   various bone and/or cartilage disorders such as sports injuries and
CC   arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC   from cartilage are useful for treating sports-related joint problems,
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 8;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 203
ADE89337
ID   ADE89337 standard; protein; 90 AA.
XX
AC   ADE89337;
XX
DT   29-JAN-2004  (first entry)
XX
DE   Human PRO polypeptide #237.
XX
KW   Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW   tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW   cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW   liver; microvascular endothelial cell; glucose; FFA;
KW   skeletal muscle cell; adipocyte cell; pericyte cell;
KW   inner ear utricular supporting cell; T-lymphocyte cell;
KW   endothelial cell tube formation; bone disorder; cartilage disorder;
KW   sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW   rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW   immune system cell infiltration.
XX
OS   Homo sapiens.
XX
PN   US2003199062-A1.
XX
PD   23-OCT-2003.
XX
PF   17-APR-2002; 2002US-00124823.
XX
PR   31-MAR-1997;   97WO-US005230.
PR   12-JUN-1998;   98WO-US012456.
PR   14-JUL-1998;   98WO-US014552.
PR   28-AUG-1998;   98WO-US017888.
PR   10-SEP-1998;   98WO-US018824.
PR   14-SEP-1998;   98WO-US019093.
PR   14-SEP-1998;   98WO-US019094.
PR   14-SEP-1998;   98WO-US019177.
PR   16-SEP-1998;   98WO-US019330.
PR   17-SEP-1998;   98WO-US019437.
PR   07-OCT-1998;   98WO-US021141.
PR   29-OCT-1998;   98WO-US022991.
PR   29-OCT-1998;   98WO-US022992.
PR   20-NOV-1998;   98WO-US024855.
PR   01-DEC-1998;   98WO-US025108.
PR   05-JAN-1999;   99WO-US000106.
PR   08-MAR-1999;   99WO-US005028.
PR   10-MAR-1999;   99WO-US005190.
PR   10-MAR-1999; 2000WO-US006319.
PR   20-APR-1999;   99WO-US008615.
PR   14-MAY-1999;   99WO-US010733.
PR   02-JUN-1999;   99WO-US012252.
PR   01-SEP-1999;   99WO-US020111.
PR   08-SEP-1999;   99WO-US020594.
PR   13-SEP-1999;   99WO-US020944.
PR   15-SEP-1999;   99WO-US021090.
PR   15-SEP-1999;   99WO-US021547.
PR   05-OCT-1999;   99WO-US023089.
PR   29-NOV-1999;   99WO-US028214.
PR   30-NOV-1999;   99WO-US028313.
PR   30-NOV-1999;   99WO-US028409.
PR   01-DEC-1999;   99WO-US028301.
PR   01-DEC-1999;   99WO-US028634.
PR   02-DEC-1999;   99WO-US028551.
PR   02-DEC-1999;   99WO-US028564.
PR   02-DEC-1999;   99WO-US028565.
PR   16-DEC-1999;   99WO-US030095.
PR   20-DEC-1999;   99WO-US030911.
PR   20-DEC-1999;   99WO-US030999.
PR   22-DEC-1999;   99WO-US030720.
PR   30-DEC-1999;   99WO-US031243.
PR   30-DEC-1999;   99WO-US031274.
PR   05-JAN-2000; 2000WO-US000219.
PR   06-JAN-2000; 2000WO-US000277.
PR   06-JAN-2000; 2000WO-US000376.
PR   11-FEB-2000; 2000WO-US003565.
PR   18-FEB-2000; 2000WO-US004341.
PR   18-FEB-2000; 2000WO-US004342.
PR   22-FEB-2000; 2000WO-US004414.
PR   24-FEB-2000; 2000WO-US004914.
PR   24-FEB-2000; 2000WO-US005004.
PR   01-MAR-2000; 2000WO-US005601.
PR   02-MAR-2000; 2000WO-US005746.
PR   02-MAR-2000; 2000WO-US005841.
PR   15-MAR-2000; 2000WO-US006884.
PR   20-MAR-2000; 2000WO-US007377.
PR   21-MAR-2000; 2000WO-US007532.
PR   30-MAR-2000; 2000WO-US008439.
PR   17-MAY-2000; 2000WO-US013705.
PR   22-MAY-2000; 2000WO-US014042.
PR   30-MAY-2000; 2000WO-US014941.
PR   02-JUN-2000; 2000WO-US015264.
PR   28-JUL-2000; 2000WO-US020710.
PR   11-AUG-2000; 2000WO-US022031.
PR   23-AUG-2000; 2000WO-US023522.
PR   24-AUG-2000; 2000WO-US023328.
PR   08-NOV-2000; 2000WO-US030952.
PR   10-NOV-2000; 2000WO-US030873.
PR   01-DEC-2000; 2000WO-US032678.
PR   20-DEC-2000; 2000US-00747259.
PR   20-DEC-2000; 2000WO-US034956.
PR   28-FEB-2001; 2001US-00796498.
PR   28-FEB-2001; 2001WO-US006520.
PR   01-MAR-2001; 2001WO-US006666.
PR   09-MAR-2001; 2001US-00802706.
PR   14-MAR-2001; 2001US-00808689.
PR   22-MAR-2001; 2001US-00816744.
PR   05-APR-2001; 2001US-00828366.
PR   10-MAY-2001; 2001US-00854208.
PR   10-MAY-2001; 2001US-00854280.
PR   18-MAY-2001; 2001US-00860216.
PR   25-MAY-2001; 2001US-00866028.
PR   25-MAY-2001; 2001US-00866034.
PR   25-MAY-2001; 2001WO-US017092.
PR   01-JUN-2001; 2001US-00872035.
PR   01-JUN-2001; 2001WO-US017800.
PR   05-JUN-2001; 2001US-00874503.
PR   14-JUN-2001; 2001US-00882636.
PR   19-JUN-2001; 2001US-00886342.
```

PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-041360/04.
DR N-PSDB; ADE89336.
XX
PT Novel isolated PRO polypeptide useful for treating diabetes, hyper- or
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart
PT attack, various coagulation disorders, tumors.
XX
PS Claim 12; SEQ ID NO 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

```
  Query Match             100.0%;  Score 462;  DB 8;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
```

RESULT 204
ADE18476
ID ADE18476 standard; protein; 90 AA.
XX
AC ADE18476;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003194794-A1.
XX
PD 16-OCT-2003.
XX
PF 17-APR-2002; 2002US-00125805.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.

PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-021079/02.
DR N-PSDB; ADE18475.
XX
PT New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or
PT PRO4978, for use in molecular biology, chromosome and gene mapping, in
PT generating antisense RNA and DNA, and in gene therapy.
XX
PS Claim 12; SEQ ID NO 474; 638pp; English.
XX

CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC polypeptides are also useful for treating various mammalian haemoglobin-
CC associated disorders such as various thalassaemias and conditions which
CC may benefit from enhanced local immune system cell infiltration. This
CC sequence represents a human PRO polypeptide of the invention. Note: The
CC sequence data for this patent is also available in electronic format from
CC USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 90 AA;

Query Match 100.0%; Score 462; DB 8; Length 90;
Best Local Similarity 100.0%; Pred. No. 9.8e-49;
Matches 90; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
Db 1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
Db 61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90

RESULT 205
ADE88785
ID ADE88785 standard; protein; 90 AA.
XX
AC ADE88785;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human PRO polypeptide #237.
XX
KW Human; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003199054-A1.

XX
PD 23-OCT-2003.
XX
PF 12-APR-2002; 2002US-00121054.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 07-OCT-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022991.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 99WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US005190.
PR 10-MAR-1999; 2000WO-US006319.
PR 20-APR-1999; 99WO-US008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
DR WPI; 2004-041356/04.
DR N-PSDB; ADE88784.
XX
PT Novel secreted and transmembrane polypeptides, PRO useful for treating
PT bone disorders, arthritis, heart attack, injuries, tumors, and
PT stimulating release of TNF-alpha from human blood.
XX
PS Claim 12; SEQ ID NO 474; 638pp; English.
XX
CC The invention relates to isolated human PRO polypeptides (secreted and
CC transmembrane polypeptides) and the polynucleotides encoding them. The
CC invention also relates to an antibody which specifically binds to a PRO
CC polypeptide, a method for stimulating the release of tumour necrosis
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the
CC proliferation or differentiation of chondrocyte cells and a method for
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
CC polynucleotides are useful in molecular biology, including uses as
CC hybridisation probes, in chromosome and gene mapping, in generating
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also
CC be used in preparing PRO polypeptides by recombinant techniques and in
CC generating either transgenic animals or knock-out animals which are
CC useful in the development and screening of therapeutically useful
CC reagents. The PRO polypeptides or antibodies are used in preparing a
CC medicament for treating a condition responsive to the polypeptides or
CC antibodies, such as tumours, for stimulating and inhibiting proliferation
CC of human microvascular endothelial cells, for modulating the uptake of
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for
CC stimulating differentiation of adipocyte cells, for stimulating
CC proliferation of or gene expression in pericyte cells, for stimulating
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte
CC cells, for inducing endothelial cell tube formation and for treating
CC various bone and/or cartilage disorders such as sports injuries and
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC from cartilage are useful for treating sports-related joint problems,

```
CC   articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC   polypeptides are also useful for treating various mammalian haemoglobin-
CC   associated disorders such as various thalassaemias and conditions which
CC   may benefit from enhanced local immune system cell infiltration. This
CC   sequence represents a human PRO polypeptide of the invention. Note: The
CC   sequence data for this patent is also available in electronic format from
CC   USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ   Sequence 90 AA;

  Query Match             100.0%;  Score 462;  DB 8;  Length 90;
  Best Local Similarity   100.0%;  Pred. No. 9.8e-49;
  Matches   90;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60
              ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Db          1 MTFFLSLLLLLVCEAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKTT 60

Qy         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90
              ||||||||||||||||||||||||||||||
Db         61 GKGIVKGRNLDSRGLILGAEAWGRGVKKNT 90


RESULT 206
AAU19838
ID   AAU19838 standard; protein; 222 AA.
XX
AC   AAU19838;
XX
DT   04-DEC-2001  (first entry)
XX
DE   Human novel extracellular matrix protein, Seq ID No 488.
XX
KW   Human; secreted extracellular matrix protein; immunomodulatory; Anti-HIV;
KW   antianemic; antirheumatic; antisclerotic; cardiant; vascular;
KW   cerebroprotective; thrombolytic; antimicrobial; ophthalmic; cytostatic;
KW   antialzheimers; immune/autoimmune disease; HIV infection; anaemia;
KW   human immunodeficiency virus; rheumatoid arthritis; multiple sclerosis;
KW   cancers; hyperproliferative disorder; breast neoplasm; melanoma;
KW   Sezary syndrome; Gaucher's disease; neurological diseases;
KW   Alzheimer's disease; Parkinson's disease; cardiovascular disorder;
KW   cardiac arrest; tachycardia; angina; infection; corneal infections;
KW   wound healing; immunogen; gene therapy; antisense; food additive.
XX
OS   Homo sapiens.
XX
PN   WO200155368-A1.
XX
PD   02-AUG-2001.
XX
PF   17-JAN-2001; 2001WO-US001348.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
PR   08-SEP-2000; 2000US-0232081P.
PR   12-SEP-2000; 2000US-0231968P.
PR   14-SEP-2000; 2000US-0232397P.
PR   14-SEP-2000; 2000US-0232398P.
PR   14-SEP-2000; 2000US-0232399P.
PR   14-SEP-2000; 2000US-0232400P.
PR   14-SEP-2000; 2000US-0232401P.
PR   14-SEP-2000; 2000US-0233063P.
PR   14-SEP-2000; 2000US-0233064P.
PR   14-SEP-2000; 2000US-0233065P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   25-SEP-2000; 2000US-0234998P.
PR   26-SEP-2000; 2000US-0235484P.
PR   27-SEP-2000; 2000US-0235834P.
PR   27-SEP-2000; 2000US-0235836P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239935P.
PR   13-OCT-2000; 2000US-0239937P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241221P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241786P.
PR   20-OCT-2000; 2000US-0241787P.
PR   20-OCT-2000; 2000US-0241808P.
PR   20-OCT-2000; 2000US-0241809P.
PR   20-OCT-2000; 2000US-0241826P.
PR   01-NOV-2000; 2000US-0244617P.
PR   08-NOV-2000; 2000US-0246474P.
PR   08-NOV-2000; 2000US-0246475P.
PR   08-NOV-2000; 2000US-0246476P.
PR   08-NOV-2000; 2000US-0246477P.
PR   08-NOV-2000; 2000US-0246478P.
PR   08-NOV-2000; 2000US-0246523P.
```

PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-465572/50.
DR N-PSDB; AAS31409.
XX
PT Nucleic acid molecules encoding human secreted extracellular matrix
PT proteins, used in preventing, treating or ameliorating a disorder, e.g.
PT Alzheimer's and Parkinson's diseases and cancers.
XX
PS Claim 11; SEQ ID NO 488; 577pp; English.
XX
CC The invention relates to isolated nucleic acid molecules encoding novel
CC human secreted extracellular matrix proteins (SPs). The polynucleotides
CC and proteins are used to prevent, treat a medical condition in e.g.
CC humans, mice, rabbits, goats, horses, cats, dogs, chickens or sheep. For
CC example, disorders associated with decreased expression of SPs. The SP
CC polynucleotide or a vector expressing them may be administered to treat
CC diseases by gene therapy. Antisense molecules may be administered to down
CC regulate expression of SPs by binding with the cells own genes and
CC preventing their expression. The polynucleotides may also be used as DNA
CC probes in diagnostic assays. The SPs may also be used as antigens to
CC produce antibodies and to identify modulators (agonists and antagonists)
CC of the SPs. The anti-(SP) antibodies and antagonists may also be used to
CC down regulate expression and activity of SP and as diagnostic agents for
CC detecting the presence of SPs in samples. The disorders include for
CC example: immune/autoimmune diseases (e.g. HIV (human immunodeficiency
CC virus) infections, anaemia, rheumatoid arthritis and multiple sclerosis),
CC cancers and hyperproliferative disorders (e.g. melanomas, neoplasms of
CC the breast or liver, Sezary syndrome and Gaucher's disease), neurological
CC diseases (e.g. Alzheimer's disease, Parkinson's disease) cardio-
CC /cerebrovascular disorders (e.g. cardiac arrest, tachycardia and angina),
CC infections caused by bacteria, viruses and fungi and ocular disorders
CC (e.g. corneal infections). Other uses include wound healing, maintenance
CC of organs before transplantation, support of cell culture of primary

Query Match 53.6%; Score 247.5; DB 4; Length 222;
Best Local Similarity 80.6%; Pred. No. 8.5e-22;
Matches 50; Conservative 4; Mismatches 3; Indels 5; Gaps 1;

```
Qy          5 LSLLLLLVC-----EAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKT 59
              | |::|::       ||||||||||||||||||||||||||||||||||||||||||||
Db         83 LCLVILVIAVVLGTMAIWRSNSGSNTLENGYFLSRNKENHSQPTQSSLEDSVTPTKAVKT 142

Qy         60 TG 61
              ||
Db        143 TG 144
```

Search completed: June 1, 2004, 08:21:03
Job time : 62 secs